tenofovir has been researched along with lamivudine in 804 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 234 (29.10) | 29.6817 |
| 2010's | 434 (53.98) | 24.3611 |
| 2020's | 136 (16.92) | 2.80 |
| Authors | Studies |
|---|---|
| Haefeli, WE; Ketabi-Kiyanvash, N; Lindenmaier, H; Theile, D; Weiss, J | 1 |
| Brunelle, MN; Holy, A; Lucifora, J; Neyts, J; Trepo, C; Villet, S; Zoulim, F | 1 |
| Baba, M; De Clercq, E; Shi, M; Takao, S; Wang, X | 1 |
| Ainsworth, J; Booth, C; Bradshaw, D; Geretti, AM; Malik, S; Pattery, T; Van Houtte, M; Waters, A | 1 |
| Anderson, DJ; Gottlieb, GS; Preston, BD; Pyrak, CL; Smith, RA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| DiStefano, DJ; Hazuda, DJ; Lai, MT; McKenna, PM; Miller, MD; Munshi, V; Touch, S; Tucker, TJ; Tynebor, RM; Williams, TM | 1 |
| Chen, YC; Dumond, JB; Fiscus, SA; Horton, AL; Kashuba, AD; Patterson, KB; Rezk, NL; Tappouni, HL; Tien, HC; Vourvahis, M; Yeh, RF | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| De Jonghe, S; Dumbre, SG; Herdewijn, P; Huang, C; Liu, C; Murray, MG; Pannecouque, C; Ptak, RG | 1 |
| Goldmann, S; Li, J; Liu, X; Luo, Z; Ren, Q; Wang, C; Zhang, J; Zhang, Y | 1 |
| Andrei, G; Buckheit, RW; De Jonghe, S; Groaz, E; Hartman, T; Herdewijn, P; Kalkeri, R; Luo, M; Ptak, RG; Schols, D; Snoeck, R | 1 |
| Li, L; Li, X; Li, Y; Liu, M; Lv, K; Ma, C; Tao, Z; Wang, A; Wu, S | 1 |
| Dong, Y; Jiang, C; Li, S; Liu, G; Ma, Y; Pei, Y; Tan, X; Wang, C; Wang, L; Xiang, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| De Clercq, E; Neyts, J; Ying, C | 1 |
| Berg, T; Schürmann, D; van Bömmel, F; Wünsche, T | 1 |
| Prescott, LM | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Dieterich, DT | 1 |
| Balzarini, J; Van Herrewege, Y; Vanham, G | 1 |
| Díaz, B; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P | 1 |
| Higgins, J; Huang, VY; Matthews, TB; Murry, JP; North, TW; Pedersen, NC; Van Rompay, KK | 1 |
| Benhamou, Y; Thibault, V; Tubiana, R | 1 |
| Berg, T; Hopf, U; Schernick, A; Van Bömmel, F | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Bacheler, L; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Otto, MJ; Schinazi, RF; Shi, G; Wu, JT; Zhang, H | 1 |
| Derse, D; Hill, SA; Lloyd, PA; McDonald, S; Wykoff, J | 1 |
| Crippin, J; Drechsler, H; Lisker-Melman, M; Ristig, M; Tebas, P | 1 |
| Akula, N; Chong, Y; Chu, CK | 1 |
| Buster, EH; Schalm, SW; van der Eijk, AA | 1 |
| Becker, S; Feinberg, J | 1 |
| Feinberg, J | 2 |
| Brinkman, K; Frissen, PH; Hoogewerf, M; Regez, RM; Schouten, WE; Weigel, HM | 1 |
| Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
| Benhamou, Y; Poynard, T | 1 |
| Boyle, BA | 1 |
| Benhamou, Y | 2 |
| Chung, RT; Dienstag, JL; Kuo, A | 1 |
| Ait-Khaled, M; Craig, C; Griffin, P; Stone, C; Tisdale, M | 1 |
| Thio, CL | 1 |
| Ala, A; Dieterich, DT | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J; Sagir, A | 1 |
| Lok, AS | 1 |
| Berger, A; Brodt, HR; Lennemann, TS; Lutz, T; Mösch, M; Staszewski, S; Stephan, C; Stürmer, M | 1 |
| Cheng, AK; Coakley, DF; DeJesus, E; Gallant, JE; Lu, B; Miller, MD; Pozniak, AL; Staszewski, S; Suleiman, JM; Toole, JJ | 1 |
| Benhamou, Y; Cahour, A; Katlama, C; Lada, O; Poynard, T; Thibault, V | 1 |
| Benhamou, Y; Bonyhay, L | 1 |
| Bani-Sadr, F; Molina, JM; Palmer, P; Scieux, C | 1 |
| Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG | 1 |
| Bassetti, D; Bassetti, M; Briozzo, A; Cruciani, M; Di Biagio, A; Ferrazin, A; Gatti, G; Rosso, R | 1 |
| Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T | 1 |
| Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Lagathu, C; Lombès, A; Walker, UA | 1 |
| Berger, F; Gatell, J; Hoffmann, C; Holm, S; Kuhlmann, B; Martínez, E; Mauss, S; Milinkovic, A; Schmutz, G | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
| Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
| Farthing, C; Guyer, B; Khanlou, H; Yeh, V | 1 |
| D'Agostino, C; d'Ettorre, G; Lichtner, M; Massetti, AP; Mastroianni, CM; Vullo, V | 1 |
| Amin, J; Carr, A; Cooper, DA; McAllister, J; Winston, A | 1 |
| Bower, M; Davies, E; Gazzard, B; Latham, V; Mandalia, S; Michailidis, C; Nelson, M; Stebbing, J | 1 |
| Borroto-Esodo, K; Eisenberg, EJ; Fridland, A; Miller, MD; Myrick, F; Olson, LY; Ray, AS; Vela, JE | 1 |
| Cañas, C; Casais, LA; Casanova, A; Chahri, N; Figueras, J; Gornals, J; Lopez, C; Taltavull, TC; Verdura, B | 1 |
| de Man, RA; Hansen, BE; Janssen, HL; Niesters, HG; Schalm, SW; van de Ende, M; van der Eijk, AA | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Clark, N; Guyer, B; Hawkins, T; Kearney, BP; St Claire, RL; Veikley, W | 1 |
| Brun-Vézinet, F; Collin, G; Delaunay, C; Descamps, D; Flandre, P; Landman, R; Miller, M; Peytavin, G; Trylesinski, A | 1 |
| Freeman, A; Harvey, R; Hazen, R; Lanier, ER; Ross, L | 1 |
| Kuritzkes, DR | 1 |
| Berger, DS; Gallant, JE; Johnson, J; Liao, Q; Lim, ML; Rodriguez, AE; Ross, L; Shaefer, MS; Weinberg, WG; Young, B | 1 |
| Girault, V | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Osterhaus, AD; van der Eijk, AA; van der Ende, ME | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Roche, B; Samuel, D | 1 |
| Benhamou, Y; Fleury, H; Katlama, C; Le Teuff, G; Pellegrin, I; Piketty, C; Rozenbaum, W; Trimoulet, P; Trylesinski, A; Urbinelli, R | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
| Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
| Sherman, M | 1 |
| Schiff, ER; Schreibman, IR | 1 |
| Funk, A; Gerlich, WH; Hartmann, H; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Wend, UC; Will, H; Willems, WR | 1 |
| Antunes, F; Chiesi, A; Goebel, FD; Katlama, C; Knysz, B; Ledergerber, B; Lundgren, JD; Mocroft, A; Phillips, AN; Reiss, P | 1 |
| Carr, A | 1 |
| Borroto-Esoda, K; Miller, MD; Myrick, F; Ray, AS; Vela, JE | 1 |
| Hammerstrom, TS; Laessig, KA; Lewis, LL | 1 |
| Amiel, C; Guessant, S; Kara, A; Lebrette, MG; Marechal, Eda S; Pialoux, G; Quercia, R; Renaud, S; Schneider, V; Thevenet, S | 1 |
| Jenny-Avital, ER | 1 |
| Brenner, BG; Doualla-Bell, F; Essex, M; Frankel, F; Moisi, DD; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
| Piacenti, FJ | 1 |
| Berg, T; Feucht, HH; Hüppe, D; Möller, B; Sarrazin, C; Spengler, U; van Bömmel, F; Wiedenmann, B; Zöllner, B | 1 |
| Fätkenheuer, G; Lehmann, C; Wyen, C | 1 |
| Cheng, A; Lu, B; Margot, NA; Miller, MD | 1 |
| Grant, RM; Levy, V | 1 |
| Chizzolini, C; Landis, T; Perren, F; Pot, C; Ribi, C; Tiercy, JM; Vokatch, N | 1 |
| Margot, NA; Miller, MD; Waters, JM | 1 |
| Farthing, C; Khanlou, H | 1 |
| Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E | 1 |
| Barreiro, P; Camino, N; Díaz-Pollán, B; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Ramos, B; Soriano, V | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Bernard-Henry, C; Cheneau, C; de Mautort, E; Hess, G; Krebs, M; Lang, JM; Partisani, M; Priester, M; Rey, D | 1 |
| d'Ettorre, G; Mastroianni, CM; Vullo, V | 1 |
| Mellors, JW; Parikh, UM; Sheen, CW; Sluis-Cremer, N; Torres, PS; Zelina, S | 1 |
| Hester, J; Jain, MK; Lee, WM; Parekh, NK | 1 |
| Diller, R; Thompson, K | 1 |
| Attar, N; Comanor, L; Elkin, C; Jain, MK; Keiser, P; Kipnis, P; Lee, WM; Leung, K; Ocampo, A; White, C | 1 |
| Boucher, S; Fleury, H; Lavignolle-Aurillac, V; Masquelier, B; Neau, D; Ragnaud, JM; Recordon-Pinson, P; Schrive, MH | 1 |
| Lok, AS; Tan, J | 1 |
| Balestra, E; Caliò, R; Cappellacci, L; Franchetti, P; Grifantini, M; Magnani, M; Perno, CF; Pierigé, F; Rossi, L; Serafini, S | 1 |
| Berger, A; Faust, D; Stuermer, M; Teuber, G; Trojan, J | 1 |
| De Munter, P; Schrooten, Y; Van Laethem, K; Van Ranst, M; Van Wijngaerden, E; Vandamme, AM; Verbesselt, R | 1 |
| Ananworanich, J; Chetchotisakd, P; Gayet-Ageron, A; Hirschel, B; Jupimai, T; Le Braz, M; Prasithsirikul, W; Rooney, JF; Ruxrungtham, K; Ubolyam, S | 1 |
| Rimland, D; Rouphael, NG; Talati, NJ | 1 |
| Dore, GJ; Matthews, GV | 1 |
| Benech, H; Da Silva, D; Durand-Gasselin, L; Grassi, J; Pruvost, A | 1 |
| Kagan, RM; Lee, TS; Lewinski, MA; Lloyd, RM; Potts, SJ; Ross, L | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Gripshover, B; Gupta, S; Hammond, SP; Hatano, H; Hu, Z; Kalayjian, RC; Kuritzkes, DR; Smith, D; Whitcomb, J; Wild, M | 1 |
| Antenozzi, S; Hulse, S; Luque, A; Shahzad, U; Smith, B; Tanzman, E; Wang, D | 1 |
| Calvez, V; Chaix, ML; Delaugerre, C; Girard, PM; Katlama, C; Marcelin, AG; Morand-Joubert, L; Soulié, C | 1 |
| Mellors, JW; Parikh, UM; Sluis-Cremer, N; Zelina, S | 1 |
| Celesia, BM; Massimino, SD; Mavilla, S; Mughini, MT; Nunnari, G; Onorante, A; Russo, R | 1 |
| Garcia-Gasco, P; Sheldon, J; Soriano, V | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Cohen, DE; Golub, SA; Mayer, KH; Rosenthal, L | 1 |
| Daniels, E; Gaglio, PJ; Sterling, R; Tedaldi, E | 1 |
| Ayliffe, U; Dervisevic, S; Garcia-Diaz, A; Geretti, AM; Gilson, R; Johnson, M; Nebbia, G; Smith, C; Tedder, R | 1 |
| Doerr, HW; Staszewski, S; Stürmer, M | 1 |
| Bozdayi, AM; Karaaslan, H; Karatayli, E; Karayalçin, S; Kayhan, H; Sahin, F; Türkyilmaz, AR; Yurdaydin, C | 1 |
| Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Crumpacker, CS; Gilde, LR; Gotuzzo, E; Isaacs, RD; Kovacs, C; Markowitz, M; Mendo, F; Miller, MD; Morales-Ramirez, JO; Nguyen, BY; Prada, G; Ratanasuwan, W; Teppler, H; Wan, H; Wenning, LA | 1 |
| Clayton, MM; Feitelson, MA; Schinazi, RF; Sun, B | 1 |
| Agrofoglio, L; Bénech, H; Negredo, E; Pruvost, A; Théodoro, F | 1 |
| Chantratitra, W; Kiertiburanakul, S; Manosuthi, W; Sungkanuparph, S | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; Dejesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Holmes, CB; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Colson, P; Henry, M; Solas, C; Tamalet, C; Tomei, C; Villacian, J | 1 |
| Balestra, E; Cappellacci, L; Franchetti, P; Grifantini, M; Magnani, M; Perno, CF; Petrelli, R; Pierigé, F; Rossi, L; Serafini, S; Vita, P | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Hidalgo, A; Palacios, R; Rivero, A; Santos, J; Terrón, A | 1 |
| Bill, R; Cohen, D; Fisher, A; Grasso, C; Mayer, KH; Mimiaga, MJ; Van Derwarker, R | 1 |
| Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG | 1 |
| Janssen, HL; Reijnders, JG | 1 |
| Carosi, G; Ceresoli, F; Cologni, G; Cossarizza, A; Costarelli, S; Gargiulo, F; Lapadula, G; Magoni, M; Manca, N; Nasi, M; Nichelatti, M; Pinti, M; Quiros-Roldan, ME; Torti, C | 1 |
| Calza, L; Manfredi, R | 2 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Byun, KS; Choe, WH; Kim, BK; Kim, GH; Ko, SY; Kwon, SY; Lee, CH; Yeon, JE | 1 |
| Ananworanich, J; Côté, HC; Hill, A; Hirschel, B; Jupimai, T; Kerr, SJ; Laopraynak, N; Nuesch, R; Ruxrungtham, K; Saenawat, S | 1 |
| Herrera, L; Moreno, S; Sánchez-de la Rosa, R | 1 |
| Mauss, S | 1 |
| Ayoub, WS; Keeffe, EB | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Galindo, MJ; Iribarren, J; Llibre, JM; Martinez-Picado, J; Negredo, E; Pérez-Alvarez, N; Schapiro, J | 1 |
| Calabresi, A; Carosi, G; Cologni, G; Costarelli, S; Lapadula, G; Puoti, M; Quiros-Roldan, E; Tirelli, V; Torti, C; Zaltron, S | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA | 1 |
| Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA | 1 |
| Cortes, C; Domingo, P; Ferrer, E; Gatell, JM; Gutierrez, M; Leon, A; Niubo, J; Pedrol, E; Podzamczer, D; Puig, T; Sanchez, P; Veloso, S | 1 |
| Butler, SD; Cote, PJ; George, AL; Gerin, JL; Menne, S; Tennant, BC; Tochkov, IA; Xiong, S; Zhu, Y | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Amin, J; Avihingsanon, A; Bowden, S; Cooper, DA; Dore, GJ; Lewin, SR; Locarnini, S; Marks, P; Matthews, GV; Petcharapirat, P; Rerknimitr, R; Ruxrungtham, K; Sasadeusz, J | 1 |
| Andrews, M; Condoluci, DV; Luber, AD | 1 |
| Hsu, R; Lanier, ER; Oie, KL; Pappa, KA; Ross, LL; Rouse, EG | 1 |
| Morrow, JS; Redfield, RR | 1 |
| Beckebaum, S; Cicinnati, VR; Gerken, G; Sotiropoulos, GC | 1 |
| del Arco, A; Gálvez, MC; Gutiérrez-Ravé, V; Hidalgo, C; Lozano, F; Muñoz, L; Palacios, R; Ríos, MJ; Rivero, A; Santos, J | 1 |
| Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
| Canbay, A; Gerken, G; Gerlich, WH; Jochum, C; Katsounas, A; Schlaak, J | 1 |
| Gerondelis, P; Irlbeck, DM; Lanier, E; Parkin, N; Ross, LL; Rouse, E; St Clair, MH; Trinh, L; Underwood, MR | 1 |
| Allavena, C; Calvez, V; Chavanet, P; Diemer, M; Duong, M; Hoen, B; Hoizey, G; Lang, JM; May, T; Meyer, P; Peytavin, G; Rey, D; Schmit, JL; Schmitt, MP; Spire, B | 1 |
| Burgisser, P; Cavassini, M; Giulieri, SG; Günthard, HF; Knoepfel, SA; Metzner, KJ; Rauch, P; Yerly, S | 1 |
| Amini-Bavil-Olyaee, S; Lutz, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| Buti, M | 2 |
| Sarmento E Castro, R; Sheldon, J; Soriano, V | 1 |
| González-Diéguez, ML; Rodríguez, M | 1 |
| Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Lewin, SR; Locarnini, SA; Marks, P; Matthews, G; Perelson, AS; Ribeiro, RM; Ruxrungtham, K | 1 |
| Parienti, JJ | 2 |
| Arrifin, N; Audsley, J; Ayres, A; Bartholomeusz, A; Crowe, SM; Lewin, SR; Locarnini, SA; Mijch, A; Sasadeusz, J; Yuen, LK | 1 |
| Buster, EH; Janssen, HL; Schalm, SW | 1 |
| Ambrose, Z; Herman, BD; Moore, KL; Nissley, DV; Sheen, CW; Sluis-Cremer, N; Tachedjian, G; Zelina, S | 1 |
| Colombo, M; Lampertico, P | 1 |
| Alvarez-Uria, G; Ratcliffe, L; Vilar, J | 1 |
| Baumert, TF; Doffoel, M; Fafi-Kremer, S; Gut, JP; Habersetzer, F; Pastor, R; Schvoerer, E; Stoll-Keller, F | 1 |
| Moreno, V; Valencia, ME | 1 |
| Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| Albrecht, H | 1 |
| Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F | 1 |
| Gills Ray, VL; Lee, H; Silkiss, RZ | 1 |
| Belsey, E; Berzins, B; Chen, D; Choi, J; da Silva, B; Gerschenson, M; Kim, C; Libutti, DE; McComsey, GA; Murphy, RL; Shore, J; Taiwo, B; Weinstein, J | 1 |
| Ham, MY; Holt, C; Saab, S; Stone, MA; Tong, M | 1 |
| Angus, PW; Patterson, SJ | 1 |
| Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y | 1 |
| Arnaiz, JA; Arranz, JA; Arribas, JR; Barragán, P; Barrufet, P; Blanco, JL; Casas, E; Clotet, B; Cosín, J; Cruceta, A; Curran, A; Dalmau, D; Ferrer, E; Gatell, JM; González, A; Gutiérrez, F; Knobel, H; Llibre, JM; Loncá, M; Mallolas, J; Martínez, E; Miró, JM; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Sanz, J; Segura, F | 1 |
| Cabié, A; Chêne, G; Girard, PM; Katlama, C; Mercié, P; Michelet, C; Monchecourt, F; Morand-Joubert, L; Pétour, P; Trylesinski, A; Verdon, R | 1 |
| Abdel Razek, W; Belghiti, J; Durand, F; Francoz, C; Lada, O; Marcellin, P; Moucari, R; Valla, D | 1 |
| Borroto-Esoda, K; Harris, J; Lansdon, EB; Miller, MD; O'Neal, W; Svarovskaia, ES; Wakeford, C; Waters, JM; White, KL | 1 |
| Dauer, B; Gute, P; Khaykin, P; Klauke, S; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Buffet, C | 1 |
| Arasteh, K; Ebrahimi, R; Fenske, S; Freiwald, M; Gallo, L; Kuhlmann, B; Mertenskoetter, T; Ranneberg, R; Weitner, L | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Cohen, C; Dejesus, E; Elion, R; Gathe, JC; Ha, B; Hsu, RK; Lanier, R; Paulsen, D; Redfield, RR; Ross, L; Yau, L | 1 |
| Brancaccio, G; Gaeta, GB; Nardiello, S; Precone, V; Sgrò, G; Stornaiuolo, G | 1 |
| Andreotti, M; Antonelli, G; Ceccarelli, G; d'Ettorre, G; Massetti, P; Mastroianni, CM; Rizza, C; Turriziani, O; Vella, S; Vullo, V | 1 |
| Cheng, AK; Enejosa, J; Margot, NA; McColl, DJ; Miller, MD | 1 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Beltrame, A; Bozzano, F; Cenderello, G; Costa, P; De Maria, A; Di Biagio, A; Fenoglio, D; Ferrea, G; Pagano, G | 1 |
| Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N | 1 |
| Barr, JR; Cong, ME; Garcia-Lerma, JG; Heneine, W; Holder, A; Kuklenyik, Z; Martin, A; Pau, CP; Pirkle, JL; Youngpairoj, AS; Zheng, Q | 1 |
| Hill, A; Sawyer, W | 1 |
| Boccafoglio, F; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Soldani, F | 1 |
| Amin, J; Baker, D; Bloch, M; Carr, A; Cooper, DA; Emery, S; Martin, A | 2 |
| Reiss, P | 1 |
| Lin, Q; Zhang, DZ | 1 |
| Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW | 1 |
| Collier, AC; Daar, ES; Farajallah, A; Fischl, MA; Geiseler, PJ; Godfrey, C; Ha, B; Jahed, NC; Johnson, VA; Katzenstein, D; Koletar, SL; Mollan, K; Myers, L; Peeples, L; Rooney, JF; Sax, PE; Tierney, C; Woodward, WC | 1 |
| Berg, T; Böcher, WO; Buggisch, P; de Man, RA; Deterding, K; Erhardt, A; Feucht, HH; Hüppe, D; Möller, B; Petersen, J; Reinders, JG; Rhode, P; Sarrazin, C; Spengler, U; Stein, K; Trojan, J; van Bömmel, F; Wasmuth, HE; Wedemeyer, H; Wiedenmann, B | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Cohen, C; DeJesus, E; Elion, R; Gerondelis, P; Ha, B; Horton, J; Lanier, ER; Ross, LL; Rouse, E | 1 |
| Barragán, P; Casamitjana, R; Deulofeu, R; Gatell, JM; Gutiérrez, F; Larrousse, M; Loncá, M; Mallolas, J; Martínez, E; Pérez, I; Pich, J; Podzamczer, D | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Lau, GK | 1 |
| Bruzzone, B; Colao, G; De Silvestri, A; Di Biagio, A; Di Pietro, M; Maserati, R; Re, MC; Tinelli, C; Uglietti, A; Zazzi, M | 1 |
| Marcellin, P; Piratvisuth, T; Sung, J | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| Landman, GW; Soonawala, D | 1 |
| Chan, HL; Han, KH; Hou, JL; Kao, JH; Lui, YY; Mihm, U; Mohamed, R; Piratvisuth, T; Teo, EK; Tsoi, KK; Wong, GL; Wong, VW | 1 |
| Chee, GM; Poordad, F | 1 |
| Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C | 1 |
| Jiang, L; Yan, LN | 1 |
| Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J | 1 |
| Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T | 1 |
| Barnas, D; Bazmi, H; Bixby, C; Jemsek, J; Koontz, D; Mellors, JW | 1 |
| Chien, RN | 1 |
| Einarson, TR; Heathcote, EJ; Kowgier, M; Krahn, M; Nishikawa, Y; Pham, B; Sherman, M; Tomlinson, G; Ungar, WJ; Wong, DK; Woo, G | 1 |
| Coffin, CS; Michalak, TI; Mulrooney-Cousins, PM; Peters, MG; Roberts, JP; Terrault, NA; van Marle, G | 1 |
| Gianini, RJ; Gomes-Gouvêa, MS; Leite, OM; Locarnini, S; Martins, LG; Mendes-Correa, MC; Pinho, JR; Santana, RA; Silva, MH; Sitnik, R; Uip, DE; Yuen, L | 1 |
| Burke, A; Chirara, M; Dunn, DT; Gilks, CF; Goodall, RL; Hakim, J; Kaleebu, P; Kityo, C; Lyagoba, F; Munderi, P; Ndembi, N; Pillay, D; Robertson, V; Tugume, S; Yirrell, DL | 1 |
| Alcaro, S; Alteri, C; Antinori, A; Artese, A; Balzarini, J; Ceccherini-Silberstein, F; Costa, G; Forbici, F; Narciso, P; Perno, CF; Santoro, MM; Schols, D; Svicher, V; Tommasi, C; Van Laethem, K; Zaccarelli, M | 1 |
| Dakin, H; Fidler, C; Harper, C | 1 |
| Arribas, JR; Compston, J; Gerstoft, J; Hughes, S; Lambert, J; Lazzarin, A; Leather, D; Orkin, C; Pearce, H; Rizzardini, G; Sprenger, HG; Stellbrink, HJ; Sture, G; Van Wijngaerden, E; Zucchi, P | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Einecke, D | 1 |
| Allegri, R; Amadasi, S; Carosi, G; Cristini, G; Gatti, F; Izzo, I; Mendeni, M; Motta, D; Paraninfo, G; Quiros-Roldan, E; Torti, C | 1 |
| Goswami, S; Pande, UC; Sanyal, M; Shrivastav, PS; Singhal, P; Yadav, M | 1 |
| Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Tacke, F; Trautwein, C | 1 |
| Chotiyaputta, W; Ditah, FA; Goodwin, D; Lok, AS; Peterson, C | 1 |
| Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Angus, PW; Bowden, S; Desmond, PV; George, J; Lee, AU; Locarnini, S; Nicoll, AJ; Patterson, SJ; Roberts, SK; Sievert, W; Strasser, SI | 1 |
| Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N | 1 |
| Brown, JA; Fowler, JD; Pack, LR; Suo, Z | 1 |
| Bourlière, M; Kahloun, A; Zoulim, F | 1 |
| Benhamou, Y; Pais, R | 1 |
| Marcellin, P | 1 |
| Christodoulou, DK; Katsanos, KH; Tsianos, EV; Tsianos, VE; Vagias, I; Zervou, E; Zioga, H; Zois, CD | 1 |
| Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF | 1 |
| Borroto-Esoda, K; Goodman, DD; Margot, NA; McColl, DJ; Miller, MD; Svarovskaia, ES; Zhong, L; Zhou, Y | 1 |
| Bartels, M; Berg, T; Hartmann, J; Jonas, S; Karlas, T; Maier, M; Mössner, J; Tillmann, HL; Weimann, A; Wiegand, J | 1 |
| Leung, N | 1 |
| Papatheodoridis, GV | 1 |
| Zoulim, F | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Alric, L; Basse, G; Daudé, M; Esposito, L; Guitard, J; Izopet, J; Kamar, N; Lavayssière, L; Rostaing, L; Sauné, K | 1 |
| Bracciale, L; Cauda, R; D'Avino, A; De Luca, A; Di Giambenedetto, S; Doino, M; Fabbiani, M; Marzocchetti, A; Navarra, P | 1 |
| Baldelli, F; Floridia, M; Francisci, D; Martinelli, L; Masini, G; Weimer, LE; Zazzi, M | 1 |
| Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Suntisuklappon, B; Tantanathip, P; Thongyen, S | 1 |
| Andersen, ES; Christensen, PB; Frigstad, SO; Kjær, M; Konopski, Z; Krarup, H; Leutscher, P; Moessner, B; Weiland, O; Weis, N; Westin, J | 1 |
| Cooper, V; Ewan, J; Fisher, M; Horne, R; Liu, HC; Moyle, GJ; Reilly, G | 1 |
| Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE | 1 |
| Tornai, I | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Gutiérrez, F; López, N; Masiá, M; Padilla, S; Ramos, JM; Robledano, C | 1 |
| Barragán, P; Bonet, R; Curran, A; Gatell, JM; Knobel, H; Loncá, M; Martínez, E; Negredo, E; Ordoñez-Llanos, J; Podzamczer, D; Ribera, E; Saumoy, M | 1 |
| Benetti, S; Cassino, L; Fay, F; Quarleri, J; Tanno, H | 1 |
| Chan, K; Cooper, C; Hogg, RS; Klein, MB; Loutfy, MR; Machouf, N; Montaner, JS; Raboud, J; Rourke, SB; Tan, DH; Tsoukas, C; Walmsley, S | 1 |
| Anderson, PL; Bushman, LR; Kiser, JJ; Klein, B; Ray, ML; Rower, JE; Zheng, JH | 1 |
| Donnelly, J | 1 |
| Block, TM; Clearfield, E; Cuconati, A; Goddard, C; Guo, H; Mills, C; Morrey, JD; Motter, NE; Xiao, T; Xu, X; Yu, W; Zhao, K | 1 |
| Giles, M; Sasadeusz, J; Visvanathan, K | 1 |
| Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N | 1 |
| Borroto-Esoda, K; Curtis, M; Zhu, Y | 1 |
| Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW | 1 |
| Hull, MW; Montaner, JS | 1 |
| Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
| Ananthakrishnan, S; Garg, A; Levine, D | 1 |
| Frederiksen, CA; Langdahl, BL; Laursen, AL; Melchjorsen, J; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kityo, C; Mambule, I; Munderi, P; Reid, A; Ssali, F; Stöhr, W; Walker, AS | 1 |
| Lee, SS; Sherman, M | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Dalekos, GN; Tillmann, HL; Zachou, K | 1 |
| García-Alonso, FJ; Martín-Mateos, RM; Moreira Vicente, V | 1 |
| Angarano, G; Bellacosa, C; Graziano, G; Maggi, P; Montinaro, V; Pietanza, S; Strippoli, GF; Volpe, A | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Burugula, L; Inamadugu, JK; J V L N, SR; Matta, MK; Pilli, NR | 1 |
| Fontana, RJ; Singal, AK | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Amoroso, A; Edozien, A; Etienne-Mesubi, M; Hossain, MB; Obiefune, M; Ojoo, S; Redfield, RR; Sheneberger, R; Stafford, K | 1 |
| Kanki, PJ; Shafer, RW; Tang, MW | 1 |
| Belda, A; Borrás-Blasco, J; Casterá, E; Jiménez, I; López-Montes, L; Rosique-Robles, D | 1 |
| Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E | 1 |
| Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P | 1 |
| Barragan, P; Crespo, M; Curran, A; Falco, V; Gatell, JM; Imaz, A; Lonca, M; Martinez, E; Martinez, M; Podzamczer, D; Ribera, E; Vidal-Sicart, S | 1 |
| Arasteh, K; Boven, K; Crauwels, H; De Wet, J; Gathe, J; Gold, J; Hodder, S; Kumar, P; Mohapi, L; Short, W; Vanveggel, S | 1 |
| Brinkman, K; Furrer, H; Fux, CA; Garcia, EF; Hoek, FJ; Krediet, RT; Reiss, P; van Straalen, JP; Vrouenraets, SM; Wit, FW | 1 |
| Birn, H; Erlandsen, EJ; Jensen, D; Langdahl, BL; Laursen, AL; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Fernandes, CA; Gomes, Sde A; Mello, FC | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Bloom, A; Brown, TT; Daar, ES; Fedarko, N; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C | 1 |
| Hadziyannis, SJ | 1 |
| Chidziva, E; Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kizito, H; Kyomugisha, H; Munderi, P; Musoke, P; Nalumenya, R; Nathoo, K; Russell, EC; Spyer, M; Tumukunde, D; Walker, AS; Zalwango, E | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Goulis, I; Papanikolaou, V; Vasiliadis, T | 1 |
| Das, P; Ford, M; Holt, S; Kingdon, E; Vivek, V | 1 |
| Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Hoy, JF | 1 |
| Almasio, PL; Bertino, G; Brandolino, N; Bruno, S; Caroleo, B; Cosco, L; Di Marco, V; Foti, G; Frugiuele, P; Galdieri, A; Madonia, S; Montalto, G; Portelli, V; Russello, M; Sapienza, M; Scifo, G; Siciliano, R; Spadaro, A; Stroffolini, T; Surace, L | 1 |
| Gordon, M; Hampton, J; Johnson, B; Kuritzkes, DR; Marconi, VC; Moosa, MY; Ordonez, C; Sunpath, H; Wu, B | 1 |
| Alfieri, A; Boni, C; Brancaccio, G; Colombo, M; Ferrari, C; Gaeta, GB; Giuberti, T; Laccabue, D; Lampertico, P; Missale, G; Pesci, M; Schivazappa, S; Viganò, M | 1 |
| Chianura, L; Errante, I; Moioli, MC; Orcese, C; Orso, M; Puoti, M; Rossotti, R; Schiantarelli, C; Schlacht, I; Travi, G; Vigo, B; Villa, MR; Volonterio, A | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Giacobbe, DR; Mikulska, M; Taramasso, L; Viscoli, C | 1 |
| Gibbs, C; Guyer, B; Haddad, M; McColl, DJ; Miller, MD; Su, C | 1 |
| Akinkuotu, A; Chasela, C; Hosseinipour, MC; Jamieson, DJ; Johnson, DC; King, CC; Kourtis, AP; Maliwichi, M; Moses, A; Mwafongo, A; van der Horst, C | 1 |
| Carda-Broch, S; Casas-Breva, I; Esteve-Romero, J; Peris-Vicente, J; Rambla-Alegre, M | 1 |
| Bozdayi, AM; Cevik, E; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, SC; Seven, G; Yakut, M; Yurdaydin, C | 1 |
| Berg, T; Bock, FJ; Deterding, K; Feucht, HH; Hüppe, D; Möller, B; Trojan, J; van Bömmel, F; Wasmuth, HE; Wedemeyer, H | 1 |
| Alvarez, A; Calatayud, S; De Pablo, C; Esplugues, JV; Martí-Cabrera, M; Orden, S | 1 |
| Babiker, ZOE; Hogan, C; Ustianowski, A; Wilkins, E | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Valcour, V | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Kelleher, AD; Martin, A | 1 |
| Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R | 1 |
| Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB | 1 |
| Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O | 1 |
| Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Angeli, P; Cavallin, M; Fasolato, S; Gatta, A; Gola, E; Morando, F; Rosi, S | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Bahrami, S; Chevaliez, S; Grare, M; Hézode, C; Pawlotsky, JM | 1 |
| Ananworanich, J; Chomchey, N; Gerschenson, M; Hongchookiat, P; Jadwattanakul, T; Kerr, SJ; Kim, JH; Mathajittiphun, P; Phanuphak, N; Phanuphak, P; Pinyakorn, S; Praihirunyakit, P; Rungrojrat, P; Shikuma, C; Teeratakulpisarn, N; Valcour, V | 1 |
| Buti, M; Petersen, J | 1 |
| Basse, CD; Dia, NM; Dieng, AB; Diop, BM; Diop, SA; Fortes-Déguénonvo, L; Manga, NM; Ndaw, G; Ndour, CT; Seydi, M; Soumaré, M; Sow, PS | 1 |
| Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G | 1 |
| Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC | 1 |
| Cui, YJ; Song, ZL; Teng, DH; Zheng, H; Zheng, WP | 1 |
| Benson, P; Bredeek, UF; Brinson, C; Campo, R; Dau, L; DeJesus, E; Flaherty, J; Fralich, T; Guyer, B; Henry, K; Khanlou, H; Logue, K; Piontkowsky, D; Wang, H; White, K | 1 |
| Akyuz, F; Badur, S; Baran, B; Besisik, F; Bozbey, HU; Demir, K; Evirgen, S; Gokturk, S; Gulluoglu, M; Karaca, C; Kaymakoglu, S; Onel, D; Ormeci, AC; Soyer, OM | 1 |
| Candusso, M; Iorio, R; Liccardo, D; Riva, S; Torre, G; Tufano, M | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Gatanaga, H; Hayashida, T; Oka, S; Tanuma, J | 1 |
| de la Torre, J; del Arco, A; Olalla, J; Pombo, M; Prada, JL; Urdiales, D | 1 |
| Amarapurkar, DN; Patel, N | 1 |
| Brown, RS; Brubaker, WD; Chang, MS; Emond, JC; Guarrera, JV; Olsen, SK; Pichardo, EM; Rosenthal-Cogan, L; Stiles, JB | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M | 1 |
| Acalovschi, M; Arama, V; Bjork, S; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Marcellin, P; Mauss, S; Morais, E; Sieklucki, J; Simon, K; Usluer, G; Zarski, JP; Zeuzem, S | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Angeletti, C; Antonucci, G; Armignacco, O; Cassola, G; De Stefano, G; Girardi, E; Grossi, P; Mazzotta, F; Orani, A; Pagano, G; Petrosillo, N; Puoti, M; Sagnelli, C; Sagnelli, E | 1 |
| Bedogni, G; Cococcioni, L; Fabiano, V; Giacomet, V; Mora, S; Stucchi, S; Viganò, A; Zuccotti, GV | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Antinori, A; Bansi, L; Boumis, E; Callegaro, A; Ceccherini-Silberstein, F; Dunn, D; Fearnhill, E; Forbici, F; Francisci, D; Maggiolo, F; Mussini, C; Nicastri, E; Palamara, G; Perno, CF; Sabin, C; Santoro, MM; Zazzi, M; Zoncada, A | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Al Hawajri, N; Borroto-Esoda, K; Dény, P; Kitrinos, K; Lavocat, F; Pichoud, C; Zoulim, F | 1 |
| B, PB; Kilaru, NB; S, KS; V, PK; Valluru, RK | 1 |
| Goyal, N; Gupta, S; Kumar, A; Taneja, S; Wadhawan, M | 1 |
| Fung, J; Huang, FY; Hung, IF; Lai, CL; Liu, K; Seto, WK; Wong, DK; Yuen, MF | 1 |
| Horváth, G | 1 |
| Cardoso, SV; de Faria, PR; Loyola, AM; Servato, JP; Spini, PH; Spini, TH | 1 |
| Cauda, R; Digiambenedetto, S; Fabbiani, M; Fortuna, S; Lisi, L; Navarra, P; Ragazzoni, E | 1 |
| Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL | 1 |
| Arribas, JR; Compston, J; Domingo, P; Gartland, M; Granier, C; Moyle, GJ; Orkin, C; Pearce, H; Sedani, S; Stellbrink, HJ | 1 |
| Barreiro, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Šperl, J | 1 |
| Berhanu, R; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Ahmed-Jushuf, I; Arumainayagam, J; Carlin, EM; Chandramani, S; Das, S; Ghanem, M; Kumari, B; Pammi, M; Riddell, L | 1 |
| Bansi-Matharu, L; Bibby, D; Bulteel, N; Churchill, D; Dunn, D; Hill, T; Nelson, M; Sabin, C | 1 |
| Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F | 1 |
| Aoki, M; Desai, DV; Kodama, EN; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Cholongitas, E; Papatheodoridis, G; Pipili, C | 1 |
| Arama, V; Bjork, S; Bludzin, W; Habersetzer, F; Jinga, M; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Morais, E; Niederau, C; Simon, K; Ulusoy, S; Vermehren, J; Zarski, JP; Zeuzem, S | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL | 1 |
| Caruntu, FA; Corsa, A; Dinh, P; Fabri, M; Flaherty, JF; Fung, S; Gane, E; Gurel, S; Hann, HW; Horban, A; Husa, P; Kwan, P; Massetto, B; McHutchison, JG; Pelemis, M; Subramanian, GM | 1 |
| Calvaruso, V; Craxì, A | 1 |
| Colombo, M; Della Corte, C; Triolo, M | 1 |
| Esteban, R; Pérez-Cameo, C; Pons, M | 1 |
| Chung, RT; Fishman, JA; Wright, AJ | 1 |
| Ananworanich, J; Bowonwattanuwong, C; Bunupuradah, T; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Ruxrungtham, K; Sophonphan, J | 1 |
| Chamnanphon, M; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C | 1 |
| Byun, KS; Choe, WH; Kim, JH; Kim, YS; Kwon, SY; Lee, CH; Lee, CI; Yeon, JE; Yoon, EL | 1 |
| Bielawski, KP; Dreczewski, M; Rybicka, M; Smiatacz, T; Stalke, P; Stracewska, E; Wróblewska, A | 1 |
| Kang, Y; Lin, X; Liu, H; Lu, M; Mao, R; Qin, Y; Wang, J; Zhang, J; Zhang, Y; Zhu, H | 1 |
| Amorosa, VK; Chang, KM; De La Torre, P; Frank, I; Gross, R; Hafkin, JS; Kostman, JR; Lo Re, V; Localio, AR; Mounzer, K; Osborn, MK; Stern, JJ | 1 |
| Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Kasirye, R; Kityo, C; Mambule, I; Mugyenyi, P; Pillay, D; Walker, AS | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Chatterjee, U; Davison, S; Glass, A; Greenup, AJ; Holdaway, S; Jackson, K; Levy, MT; Locarnini, SA; Nguyen, V; Samarasinghe, D; Strasser, SI; Tan, PK | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Haskelberg, H; Kelleher, AD | 1 |
| Aberg, JA; Hollabaugh, K; Kang, M; Koletar, SL; Pham, V; Smurzynski, M; Wu, K | 1 |
| Chimbwandira, FM; Chirwa, Z; Crampin, AC; Dasgupta, AN; Glynn, JR; Jahn, A; Katundu, C; Kayange, M; Koole, O; Price, AJ; Saul, JL; Zaba, B | 1 |
| Allworth, A; Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Pocock, N | 1 |
| Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Chaikledkaew, U; Tantai, N; Tanwandee, T; Teerawattananon, Y; Werayingyong, P | 1 |
| Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Chatterjee, U; Davison, S; Glass, A; Greenup, AJ; Holdaway, S; Jackson, K; Levy, MT; Locarnini, SA; Nguyen, V; Samarasinghe, D; Tan, PK | 1 |
| Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S | 1 |
| Bethell, R; Colby-Germinario, SP; Oliveira, M; Rajotte, D; Wainberg, MA; Xu, HT | 1 |
| Bloch, N; Huber, AD; Ji, J; Kirby, KA; Landau, NR; Leslie, MD; Lucas, AD; Michailidis, E; Ong, YT; Puray-Chavez, MN; Sarafianos, SG; Schultz, ML | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| Antonopoulou, S; Chini, M; Demopoulos, CA; Fragopoulou, E; Gargalianos, P; Lazanas, MC; Mangafas, N; Papakonstantinou, VD; Psarra, K; Stamatakis, GM; Tsogas, N; Tsoupras, AB | 1 |
| Kim, JH; Kim, KH; Park, ES; Park, YK | 1 |
| Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B | 1 |
| Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N | 1 |
| Dinçkan, A; Ersoy, F; Koçak, H; Ruhi, Ç; Süleymanlar, G; Süleymanlar, İ | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Berg, T; van Bömmel, F | 1 |
| Gerlich, WH | 1 |
| Locarnini, S; Warner, N | 1 |
| Beggel, B; Kaiser, R; Neumann-Fraune, M; Obermeier, M | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Moyle, G; Parisi, SG; Serpelloni, G | 1 |
| Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N | 1 |
| Daar, ES; Gupta, SK; Ha, B; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C; Wyatt, CM | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Alcantara, L; Burak, KW; Coffin, CS; Klein, P; Myers, RP; Pang, JX; Rezaeeaval, M | 1 |
| Ehrhardt, S; Guo, N; Nelson, K; Thio, CL; Xie, C | 1 |
| Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S | 1 |
| Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Jung, EU; Kim, BH; Kim, CM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Lee, YJ; Park, JW; Park, SJ; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Enomoto, M; Hayakawa, M; Iwadate, M; Kawada, N; Murakami, Y; Tamori, A; Tanahashi, T; Umeyama, H; Yano, Y | 1 |
| Ozdogan, OC; Yegin, EG | 1 |
| Álvarez, ML; Arterburn, S; Berenguer, J; Clotet, B; Curran, A; Estrada, V; Ferrer, P; Larrousse, M; Martínez, E; Negredo, E; Pulido, F; Ribera, E; Rubio, R; Sanz, J | 1 |
| Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B | 1 |
| Hamada-Tsutsumi, S; Imamura, J; Sugiura, W; Tanaka, Y; Watanabe, T; Yokomaku, Y | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
| Andrade, JR; Barros, LM; Bertolini, DA; Carrilho, FJ; Conde, SR; de Araújo, LV; Ferreira, AC; Ferreira, AS; Galvan, J; Gomes-Gouvêa, MS; Kliemann, DA; Kunyoshi, AS; Leite, AG; Lyra, AC; Mendes-Corrêa, MC; Nastri, AC; Oikawa, MK; Piccoli, LZ; Pinho, JR; Rezende, RE; Soares, MC; Teixeira, R | 1 |
| Anderson, J; Dhar, J; Ebrahimi, R; Ewan, J; Fisher, M; Moyle, GJ; Orkin, C; Wang, H; Wilkins, E | 1 |
| Choudhary, NS; Goja, S; Menon, PB; Mohanka, R; Rastogi, A; Saigal, S; Saraf, N; Soin, AS | 1 |
| Ha, FS; Han, T; Liu, H; Liu, L; Nie, CY; Zhang, Q | 1 |
| Alonso-Villaverde, C; Ferrer, E; Martinez-Picado, J; Maso, M; Muñoz-Moreno, JA; Ouchi, D; Podzamczer, D; Prats, A; Puertas, MC; Rozas, N; Tiraboschi, JM | 1 |
| Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W | 1 |
| Caccuri, F; Caruso, A; Castelli, F; De Francesco, MA; Gargiulo, F; Giagulli, C; Spinetti, A; Zaltron, S | 1 |
| Kim, CW | 1 |
| Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O | 1 |
| Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
| Han, Y; Li, T; Li, Y; Qiu, Z; Song, X; Xie, J; Zhu, T | 1 |
| Chan, HL; Chan, HY; Lo, AO; Tse, YK; Wong, GL; Wong, VW | 1 |
| Bae, WK; Ha, SY; Jung, SK; Jwa, YJ; Kim, JW; Kim, KA; Kim, NH; Kim, YD; Lee, BH; Lee, HK; Lee, JS; Paik, WH | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombe, K; le Carrou, J; Maylin, S; Moh, R; Zoulim, F | 1 |
| Ahmadinejad, Z; Dashti, H; Jafarian, A; Kasraianfard, A; Moini, M; Najafi, A; Nassiri-Toosi, M; Salimi, J | 1 |
| Fong, TL; Hsieh, MJ; Khemichian, S; Kim, J; Limurti, J; Zhang, SR | 1 |
| Cheong, JY; Cho, HJ; Cho, SW; Kim, SS; Shin, SJ; Yoo, BM | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ | 1 |
| Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Treluyer, JM; Urien, S; Valade, E | 1 |
| Appiah, LT; Beloukas, A; Bhagani, S; Bonnett, L; Chadwick, D; Dusheiko, G; Geretti, AM; Phillips, RO; Sarfo, FS; Stockdale, AJ | 1 |
| Allegra, S; Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G; Pensi, D; Simiele, M | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Casazza, G; Colombo, M; de Franchis, R; Facchetti, F; Fraquelli, M; Iavarone, M; Invernizzi, F; Jovani, M; Lampertico, P; Loglio, A; Mangia, G; Primignani, M; Viganò, M | 1 |
| Assuied, A; De Castro, N; Fagard, C; Grinsztejn, B; Grondin, C; Molina, JM; Pilotto, JH; Sauvageon, H; Taburet, AM; Veloso, V | 1 |
| Bravo, I; Clotet, B; Llibre, JM; Martin-Iguacel, R; Ornelas, A; Paredes, R; Puig, J; Santos, JR | 1 |
| Battegay, M; Bernasconi, E; Bihl, F; Calmy, A; Caminada, AP; Cavassini, M; Ledergeber, B; Martinetti, G; Rickenbach, M; Vernazza, P; Wandeler, G; Weber, R | 1 |
| Boettler, T; Thimme, R | 1 |
| El Agheb, MO; Grange, JD | 1 |
| Cao, F; Chen, T; He, Y; Jin, L; Liu, J; Qi, C; Wang, J; Yan, T; Yang, Y; Zhang, S; Zhao, Y | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombefor, K; Mahjoub, N; Maylin, S; Moh, R; Zoulim, F | 1 |
| Ahn, SH; Chong, Y; Kang, HS; Kim, BK; Kim, DH; Kim, KH; Lee, AR; Park, ES; Park, S; Park, YK; Rhee, JK; Shin, GC; Yang, SI | 1 |
| Amin, J; Boyd, MA; Cooper, DA; Emery, S; Kelleher, AD; Losso, M; Madero, JS; Molina, JM; Moore, CL; Renjifo, B; Ruxrungtham, K; Teppler, H; Wolff, M; Wood, R | 1 |
| Amani, A; Niederau, C; Thiel, A | 1 |
| He, C; Huang, H; Liao, L; Liu, J; Ruan, Y; Shao, Y; Wang, J; Wang, Z; Xing, H; Yang, S; Yue, Y | 1 |
| Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Thongyen, S | 1 |
| Park, JG; Park, SY | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Mancini, R; Motta, R; Re, MC; Viale, P | 1 |
| Arends, J; Chene, G; Cosin, J; Dabis, F; Daikos, G; de Wit, S; Mallolas, J; Montforte, Ad; Mussini, C; Peters, L; Raben, D; Rockstroh, J; Smit, C; Zangerle, R; Zinkernagel, A | 1 |
| Boissonnault, M; Charest, L; Galanakis, C; Huchet, E; Longpré, D; Machouf, N; Murphy, D; Thomas, R; Trottier, B; Vézina, S | 1 |
| Aliosmanoglu, I; Cetinkaya, R; Erbis, H; Kocak, H; Suleymanlar, G; Ulger, BV; Yilmaz, VT | 1 |
| Lu, X; Ning, Q; Wang, HL; Yang, X | 1 |
| Kittitrakul, C; Leowattana, W; Nontprasert, A; Phumratanaprapin, W; Poovorawan, K; Sriboonvorakul, N; Tangkijvanich, P; Thu, AM; Wilairatana, P | 1 |
| Anderson, PH; Ebeling, PR; Emery, S; Fairley, CK; Kimlin, MG; Klassen, KM | 1 |
| Andreotti, M; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Marchei, E; Mwenda, R; Palombi, L; Pichini, S; Pirillo, MF; Sagno, JB; Vella, S | 1 |
| Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
| Du, S; Guo, F; Han, Y; Li, T; Li, Y; Lv, W; Qiu, Z; Song, X; Thio, CL; Wang, H; Wang, N; Xie, J; Zhu, T | 1 |
| Lytvyak, E; Mason, AL; Montano-Loza, AJ | 1 |
| Archampong, TN; Boamah, I; Flanigan, T; Gillani, FS; Kenu, E; Kwara, A; Lartey, M; Obo-Akwa, A; Sagoe, KW; Yang, H | 1 |
| Duwal, S; von Kleist, M | 1 |
| Likanonsakul, S; Nakayama, EE; Nitiyanontakij, R; Prasithsirikul, W; Sangsajja, C; Shioda, T; Suntisuklappon, B | 1 |
| Cai, WP; He, HL; Huang, SB; Ling, XM; Liu, YF; Wang, H; Wang, M; Wang, XC; Wei, FL; Wu, H; Wu, YS; Wu, ZY; Yang, L; Zhang, FJ; Zhang, WW | 1 |
| Bair, MJ; Chang, CW; Chen, CJ; Chen, MJ; Chu, CH; Hu, KC; Lee, KH; Lin, CC; Lin, SC; Liou, TC; Liu, CY; Shih, SC; Wang, HY; Wang, TE | 1 |
| Chang, SC; Chang, SY; Hung, CC; Kuo, CH; Lin, SW; Liu, WC; Su, YC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR | 1 |
| Cao, Y; Dai, CY; Hou, W; Jiang, B; Li, XM; Lu, W; Su, R; Xu, J | 1 |
| Kurmi, M; Kushwah, BS; Narayanam, M; Sahu, A; Singh, S | 1 |
| Bae, MA; Chung, HS; Jung, SW; Lee, YI; Park, CH; Park, NH; Park, YT; Shin, JW | 1 |
| Aykın, N; Çevik, F; Demirtürk, N; Doğan, N; Koca, B; Köken, T | 1 |
| Bolduc, P; Cheeseman, SH; Colgate, E; Roder, N | 1 |
| Allavena, C; Bani-Sadr, F; Cabié, A; Cheret, A; Chirouze, C; Cotte, L; Cuzin, L; Flandre, P; Katlama, C; Pugliese, P; Rey, D | 1 |
| Cheng, X; Fraenkel, L; Han, Y; Hsieh, E; Insogna, KL; Li, T; Xia, W; Yin, MT; Zhu, T | 1 |
| Battegay, M; Bernasconi, E; Braun, DL; Darling, K; Günthard, HF; Hirzel, C; Hoffmann, M; Kouyos, RD; Kovari, H; Marzel, A; Rougemont, M; Scherrer, AU; Shilaih, M | 1 |
| Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F | 1 |
| Atay, K; Canbakan, B; Durcan, E; Gültepe, İ; Hatemi, İ; Köroğlu, E; Özdemir, S; Sonsuz, A; Tuncer, M; Yurttaş, B | 1 |
| Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Salpietro, S | 1 |
| Defresne, F; Sokal, E | 1 |
| Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S | 1 |
| Yim, HJ | 1 |
| Akyildiz, M; Balci, D; Cinar, K; Dayangac, M; Gungor, G; Hazinedaroglu, S; Idilman, R; Kalkan, C; Keskin, O; Tokat, Y; Yilmaz, TU | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Fouzas, I; Giakoustidis, D; Giouleme, O; Goulis, I; Imvrios, G; Papanikolaou, V; Vasiliadis, T | 1 |
| Chang, CY; Chen, TB; Hsu, YC; Lin, JT; Mo, LR; Tseng, CM | 1 |
| Chen, B; Ju, JC; Qi, JH; Xu, L; Zhang, NN | 1 |
| Amici, R; Andreotti, M; Buonomo, E; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Scarcella, P; Vella, S | 1 |
| Brahmania, M; Brouwer, WP; Feld, J; Hansen, T; Janssen, HL; Kowgier, M; Mazzulli, T; Wong, D | 1 |
| Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J | 1 |
| Ahn, SH; Baatarkhuu, O; Han, K; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Ku, HJ; Lee, S; Park, JY | 1 |
| Asano, M; Dohi, T; Enomoto, N; Gatanaga, H; Honda, M; Inoue, T; Kaneko, S; Kawamura, YI; Matsumoto, A; Mizokami, M; Murata, K; Nishida, N; Oka, S; Sakamoto, M; Shirasaki, T; Shuno, Y; Sugiyama, M; Tanaka, E; Yano, H | 1 |
| Alioni, S; Izudi, J; Kerukadho, E; Ndungutse, D | 1 |
| Albert, J; Blaxhult, A; Carlander, C; Eriksen, J; Flamholc, L; Gisslén, M; Josephson, F; Karlström, O; Navér, L; Sönnerborg, A; Svedhem, V; Yilmaz, A | 1 |
| Carneiro, CC; Carvalho, CJ; Carvalho, WF; Chen-Chen, L; Cunha, KS; Lima, DC; Moraes Filho, AV; Silva, DM; Vale, CR; Vieira, TB | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Asari, V; Baxter, C; Garrett, N; Grobler, A; Karim, QA; Karim, SSA; Majola, N; Naicker, N; Naidoo, A; Werner, L | 1 |
| Angus, P; Bowden, S; Desmond, P; George, J; Lee, A; Lim, L; Locarnini, S; Marion, K; Nicoll, A; Patterson, S; Roberts, S; Sievert, W; Strasser, S; Thompson, A | 1 |
| Clumeck, N; de Oliveira, T; Gregson, J; Gupta, RK; Hamers, RL; Hoffmann, CJ; Hunt, G; Kaleebu, P; Kanki, P; Kantor, R; Kerschberger, B; Lockman, S; Marconi, VC; Ndembi, N; Pillay, D; Raizes, E; Shafer, RW; van Vuuren, C; Yang, C | 1 |
| Harrison, M; Matjila, M; Riemer, L; Tooke, L | 1 |
| Aurpibul, L; Bunupuradah, T; Hansudewechakul, R; Kanjanavanit, S; Kosalaraksa, P; Lumbiganon, P; Puthanakit, T; Taeprasert, P | 1 |
| Adinolfi, LE; Andreana, L; Boemio, A; Guerrera, B; Marrone, A; Pasquale, G; Rainone, I; Rinaldi, L; Ruggiero, G; Zampino, R | 1 |
| Chang, SC; Chang, SY; Chuang, YC; Huang, YS; Hung, CC; Lee, KY; Liu, WC; Sheng, WH; Su, YC; Sun, HY | 1 |
| Song, BC | 1 |
| Dixit, VK; Jain, AK; Nath, G; Singh, N; Srivastava, M | 1 |
| Arcaini, L; Gotti, M; Merli, M; Rattotti, S | 1 |
| Ahmad, S; Brima, N; Chaponda, M; Davies, C; Hay, P; Johnson, M; Kingston, M; Lewis, JM; Marshall, N; Mulka, L; Muqbill, G; Nelson, M; Shaw, J; Smith, C; Tomkins, A; Torkington, A; Waters, L; Williams, D | 1 |
| Naidoo, P; Soorju, V | 1 |
| Angarano, G; Fasano, M; Fiore, JR; Leone, A; Maggi, P; Santantonio, TA; Volpe, A | 1 |
| Lim, YS | 1 |
| Banerjee, P; Banerjee, S; Chakrabarti, S; Chakraborty, A; Chowdhury, A; Das, K; Datta, S; Ghosh, S; Khatun, M; Mondal, RK; Mukherjee, S; Pandit, P | 1 |
| Khamadi, SA; Lihana, RW; Mabeya, SN; Ngugi, C; Nyamache, AK | 1 |
| Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ | 1 |
| Capobianchi, MR; D'Offizi, G; Menzo, S; Piselli, P; Solmone, M; Vincenti, D | 1 |
| Collier, AC; Daar, ES; Freedberg, KA; Losina, E; Parker, RA; Rabideau, DJ; Sax, PE; Tierney, C | 1 |
| Ashworth, A; Barker, J; Davies, A; Feddy, L; Fedor, I; Ghazi Suliman, MA; Hayes, T; Kosmidis, C; Malagon, I; Ogungbenro, K; Stirling, S; Szabo-Barnes, A | 1 |
| He, L; Jiang, Y; Liu, X; Wang, X; Yang, Z; Zhang, S; Zhao, Y | 1 |
| Badal-Faesen, S; Brown, TT; Campbell, TB; Cardoso, SW; Erlandson, KM; Fiorillo, SP; Hakim, J; Kumarasamy, N; Kumwenda, J; Lalloo, U; Riviere, C; Sanchez, J | 1 |
| Díez-Pérez, A; González-Mena, A; Guelar, A; Güerri-Fernández, R; Herrera, S; Knobel, H; Molina-Morant, D; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Conrad, F; Govender, M; Maartens, G; Manning, K; Papavarnavas, NS | 1 |
| Abram, ME; Callebaut, C; Kulkarni, R; Margot, NA; Miller, MD; Porter, D; White, K; Wong, P | 1 |
| Liu, CJ; Su, TH | 1 |
| Kurmi, M; Singh, S | 1 |
| Hu, C; Huang, H; Li, Y; Liu, J; Yang, D; Yuan, G; Zhang, YY; Zhou, F; Zhou, Y | 1 |
| Maartens, G; Martinson, NA; Mochan, A; Muchichwa, P; Norman, J; Rakgokong, M; Sigauke, FR; Variava, E | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Gore, ML; Jatta, A; Lemoine, M; Ndow, G; Njie, R; Sabally, S; Sadiq, F; Shimakawa, Y; Sow, A; Suso, P; Tamba, S; Thursz, MR; Touré-Kane, C | 1 |
| Avihingsanon, A; Burger, DM; Gatechompol, S; Maek-A-Nantawat, W; Ruxrungtham, K; Sapsirisavat, V; Sophonphan, J; Thammajaruk, N; Thiansanguankul, W; Ubolyam, S | 1 |
| Amara, A; Diliiy Penchala, S; Else, L; Khoo, S; Lamorde, M; Olagunju, A; Waitt, C | 1 |
| Awoke, T; Birlie, B; Braekers, R; Kasim, A; Shkedy, Z | 1 |
| Ahn, JS; Jeon, HJ; Jung, SW; Kim, HR; Lee, JH; Noh, JH; Park, NH; Shin, JW; Yang, Y | 1 |
| Aboud, M; Aylott, A; Belonosova, E; Buchanan, AM; Falcó, V; Hagins, DP; Man, CY; Orrell, C; Porteiro, N; Smith, KY; Vavro, C; Walmsley, S; Wynne, B | 1 |
| Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G | 1 |
| Ahir, BK; Li, LQ; Wu, GB; Zhang, CY; Zhong, JH | 1 |
| Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D | 1 |
| Brambilla, D; Ceffa, S; De Luca, A; Liotta, G; Luhanga, R; Magid, NA; Mancinelli, S; Marazzi, MC; Palombi, L; Sidumo, ZJ; Zanelli, G | 1 |
| Agarwal, A; Alexander, PE; Chang, Y; Foroutan, F; Guyatt, GH; Hepworth, E; Lee, Y; Lesi, O; Mah Ming, J; Merglen, A; Mir, H; Mirza, R; Siemieniuk, RA; Zeraatkar, D; Zhang, Y | 1 |
| Cotarelo, M; Macías, J; Mancebo, M; Merchante, N; Merino, D; Montes-Ramírez, ML; Pérez-Pérez, M; Pineda, JA; Pulido, F; Raffo, M; Rivero-Juárez, A; Téllez, F | 1 |
| Cathcart, AL; Delaney, WE; Kitrinos, KM; Liu, Y | 1 |
| Lee, JH; Lee, YB | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Janabi, M; Kabeho, A; Mayala, H; Nicholaus, P; Nkinda, A; Pallangyo, P | 1 |
| Chun, JM; Han, YS; Hur, K; Jang, SY; Kang, MK; Kweon, YO; Lee, HJ; Lee, HW; Lee, YR; Park, JG; Park, SY; Tak, WY | 1 |
| Cottrell, ML; Kashuba, ADM; Prince, H; Schauer, AP; Sykes, C | 1 |
| Blanco, MÁ; Bonet, ML; Calleja, JL; Casado, MÁ; Fraga, E; Fuentes, J; García-Buey, ML; González, JM; Jorquera, F; Molina, E; Pascasio, JM; Pons, JA; Prieto, M; Rodríguez, M; Salmerón, J; Sánchez-Antolín, G | 1 |
| Akunuri, S; Kallampallil, J; Leong, S; Maweni, R | 1 |
| Choe, BH; Choe, JY; Kang, B; Kim, JE; Ko, JS; Lee, KJ; Yang, HR | 1 |
| Endo, T; Ito, K; Saitoh, S; Sugiura, T; Suzuki, M; Tajiri, H; Tanaka, Y; Wakano, Y | 1 |
| Becht, E; Bertoletti, A; Cheng, Y; Foster, GR; Gill, US; Hansi, NK; Kao, JH; Kennedy, PT; Kunasegaran, K; Le Bert, N; Lim, SG; Newell, EW; Rivino, L; Su, TH; Tan, DZ; Tseng, TC | 1 |
| Khoo, S; Kyohaire, I; Lamorde, M; Nakalema, S; Olagunju, A; Owen, A; Waitt, C | 1 |
| Dalzero, S; Degli Antoni, A; Floridia, M; Guaraldi, G; Liuzzi, G; Masuelli, G; Personeni, C; Pinnetti, C; Ravizza, M; Sansone, M; Spinillo, A; Tamburrini, E; Tassis, B | 1 |
| Padma, UD; Surendran, S; Udayakumar, VP | 1 |
| Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
| Chetty, T; Coutsoudis, A; Thorne, C | 1 |
| Castelli, F; Cheng, A; Cox, S; Crofoot, G; Das, M; DeJesus, E; Di Perri, G; Estrada, V; Mallon, PWG; Peyrani, P; Podzamczer, D; Post, FA; Raffi, F; Rhee, MS; Ruane, P; Winston, A; Yan, M | 1 |
| Collier, AC; Ho, RJY; Kinman, LM; Koehn, J; Kraft, JC; Lane, S; Lee, W; McConnachie, LA | 1 |
| Abdou Chekaraou, M; Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Lacombe, K; Mahjoub, N; Maylin, S; Moh, R; Zoulim, F | 1 |
| Barr, E; Chadwick, EG; Currier, JS; Hernandez-Diaz, S; Hoffman, RM; Huo, Y; Patel, K; Rough, K; Seage, GR; Shapiro, DE; Williams, PL | 1 |
| Amiel, C; Chaix, ML; Charpentier, C; Delaugerre, C; Descamps, D; Dufayard, J; Flandre, P; Grude, M; Guinard, J; Lambert-Niclot, S; Le Guillou-Guillemette, H; Maillard, A; Marcelin, AG; Mirand, A; Montes, B; Morand-Joubert, L; Mourez, T; Reigadas, S; Rodallec, A; Vallet, S | 1 |
| Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
| Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
| Alkım, C; Alkım, H; Colak, T; İyisoy, MS; Karayakar, F; Koksal, AR; Sahin, M; Şen, İ; Yetim, A | 1 |
| Asci, Z; Demir, LS; Demir, NA; Kolgelier, S; Ozcimen, S; Sumer, S; Ural, O | 1 |
| Dubrocq, G; Rakhmanina, N | 1 |
| Appiah, LT; Beloukas, A; Chadwick, D; Geretti, AM; Phillips, RO; Ruggiero, A; Sarfo, FS; Smith, C; Stockdale, AJ; Villa, G | 1 |
| Caviglia, GP; Ngatchou, D; Olivero, A; Saracco, GM; Smedile, A | 1 |
| Alam, S; Khanna, R; Lal, BB; Rawat, D; Sood, V; Verma, S | 1 |
| Jiang, X; Luo, A; Ren, H | 1 |
| Balkan, A; Gülşen, MT; Karaoğlan, İ; Namıduru, M; Şahin, A | 1 |
| Edelstein, H; Maruff, P; Robertson, K; Ross, LL; Shaefer, MS; Small, CB; Wohl, D | 1 |
| Deeks, ED | 1 |
| Chen, QY; Fang, ZL; Harrison, TJ; Hu, LP; Jia, HH; Li, KW; Liang, SJ; Ren, CC; Wang, C; Wang, XY; Yang, QL | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY | 1 |
| Eberle, J; Kroidl, A | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Cahn, P; Clarke, AE; Currie, A; Fettiplace, A; Gartland, M; Girard, PM; Hung, CC; Madero, JS; Man, C; Ortiz, R; Pappa, K; Rockstroh, JK; Sievers, J; Smith, K; Tenorio, AR; Underwood, M; Wynne, B | 1 |
| Naing, C; Poovorawan, Y; Tong, KS | 1 |
| Baptiste, SL; Etya'ale, HM; Taro, TB | 1 |
| Della Pepa, R; Di Perna, M; Giordano, A; Giordano, C; Lucignano, M; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, C; Trastulli, F; Zacheo, I | 1 |
| Kan, W; Leng, X; Liao, L; Liu, P; Ruan, Y; Shao, Y; Wang, J; Xing, H; Xu, W; Yan, J; You, Y; Zuo, Z | 1 |
| Arendt, G; Orhan, E; Schlonies, S; Stüve, O | 1 |
| Heldwein, S; Jaeger, H; Noe, S; Page, M; Wolf, E | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Acosta, RK; Chang, S; Garner, W; Lutz, J; Majeed, S; Martin, H; Martin, R; Quirk, E; SenGupta, D; Wei, X; White, KL; Willkom, M | 1 |
| Chendi, BH; Eyoh, A; Ikomey, GM; Jacobs, GB; Lyonga, E; Mesembe, M; Okomo Assoumou, MC; Yekwa, EL | 1 |
| Abebo, TA; Altaye, AA; Asfaw, FT; Bekele, FB; Hibistu, DT; Kebede, HG; Laelago, T; Lukas, K; Tesfaye, DJ; Turuse, EA | 1 |
| Hwang, C; Martin, EA; Orkin, C | 1 |
| Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Huang, JP; Huang, WH; Luo, SD; Luo, XL; Mo, LD; Ni, ZY; Su, GS; Su, HZ; Wu, JY | 1 |
| Bickel, M; Cahn, P; Greaves, W; Hanna, GJ; Hwang, C; Johnson, M; Kumar, P; Kumar, S; Mallolas, J; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Zhou, Y | 1 |
| Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y | 1 |
| Barber, TJ | 1 |
| Belle, SH; Bzowej, NH; Chung, R; Khalili, M; Li, R; Smith, CI; Terrault, N; Tran, TT; Tsai, N | 1 |
| Amariles, P; Castañeda, C; Galindo, J; Mueses-Marín, HF | 1 |
| Beksinska, M; Brown, TT; Eneh, P; Fowler, MG; Isingel, E; Kabwigu, S; Kaiser, T; Kiweewa Matovu, F; Nakalega, R; Nicol, MR; Staley, C; Sykes, C | 1 |
| Chang, SY; Chen, GJ; Cheng, A; Chuang, YC; Huang, SH; Huang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Su, YC; Sun, HY | 1 |
| Boulware, DR; Lukande, R; Meya, DB; Namuju, OC; Nicol, MR; Pastick, KA; Rhein, J; Taylor, J; Williams, DA | 1 |
| Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J | 1 |
| Chan, TM; Fung, J; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Wong, DK; Yap, DY; Yuen, MF | 1 |
| Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M | 1 |
| Katzenstein, D; Kouamou, V; Makadzange, AT; Manasa, J; McGregor, AM; Ndhlovu, CE | 1 |
| Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA | 1 |
| Badshah, C; DeJesus, E; Goldstein, D; Hanna, GJ; Hepler, D; Hwang, C; Johnson, M; Kumar, S; Mallolas, J; Molina, JM; Pozniak, A; Rodgers, A; Sklar, P; Teal, V; Teppler, H; Wong, A | 1 |
| Kimura, A; Mizokami, M; Murata, K; Noguchi, M; Sugiyama, M; Suizu, F; Tsukuda, S; Watashi, K | 1 |
| Gao, S; Gui, X; Ke, H; Xiong, Y; Yang, R | 1 |
| Chetty, M; De Sousa Mendes, M | 1 |
| Borghi, V; Di Giambenedetto, S; Francisci, D; Franzetti, M; Giacomelli, A; Lai, A; Lepore, L; Lombardi, F; Maggiolo, F; Magnani, G; Monno, L; Paolucci, S; Pecorari, M; Rusconi, S; Vicenti, I | 1 |
| Saag, MS | 1 |
| Bela, B; Ibrahim, F; Kusumaningrum, A; Yunihastuti, E | 1 |
| Huang, YS; Hung, CC; Ko, WC; Lee, YC; Lee, YT; Li, CW; Lin, JJ; Lin, KY; Lin, SP; Liu, CE; Tang, HJ; Wang, NC; Yang, HJ | 1 |
| Chadwick, EG; Correia, KF; Crowell, CS; DiPerna, A; Hazra, R; Seage, GR; Smith, R; Van Dyke, RB; Williams, PL; Yildirim, C | 1 |
| Balakasi, K; Bardon, AR; Dovel, K; Fox, M; Haambokoma, M; Hoffman, RM; Hubbard, J; Kakwesa, G; Kalua, T; Moyo, C; Pisa, P; Rosen, S; Sanne, I; Siwale, Z; Xulu, T | 1 |
| Chi, BH; Fairlie, L; Farhad, M; Fenton, T; Fowler, MG; Moodley, D; Naik, S; Nakabiito, C; Stringer, JSA; Venkatesh, KK | 1 |
| Datir, R; Derache, A; Gregson, J; Gupta, RK; Perno, CF; Pillay, D; Rhee, SY; Shafer, RS | 1 |
| Zhang, D; Zhang, Q; Zhu, F | 1 |
| Fischer, A; Gumede, SB; Lalla-Edward, ST; Venter, WDF | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Asboe, D; Dunn, DT; Gilson, R; Hill, T; Mackie, NE; Pozniak, A; Sabin, CA; Stirrup, OT; Tostevin, A | 1 |
| Li, A; Li, C; Li, H; Li, W; Li, X; Xia, W | 1 |
| Lodi, VJC; Monteiro, JCMS; Pires, CAA; Rego, RM | 1 |
| Aboud, M; Baril, JG; Bogner, J; Eron, J; Falcó, V; Gartland, M; Hung, CC; Koteff, J; Maggiolo, F; Man, CY; Mills, A; Pappa, KA; Sievers, J; Slim, J; Smith, KY; Tenorio, AR; Underwood, M; Urbaityte, R; Wynne, B | 1 |
| Babudieri, S; Bagella, P; Bandiera, F; Calvisi, DF; Fiore, V; Garrucciu, G; Madeddu, G; Mannu, F; Melis, M; Muredda, AA; Ortu, S; Zaru, S | 1 |
| An, M; Ding, H; Han, X; Li, S; Ouyang, J; Wang, L; Zhang, M; Zhao, B | 1 |
| DiBenedetto, A; Fackler, P; Fan, L; Iwamoto, M; Khalilieh, S; Stoch, SA; Triantafyllou, I; Vallee, MH; Yee, KL | 1 |
| Ebeshi, BU; Elei, S; Kashimawo, AJ; Orubu, S; Soyinka, JO; Vaikosen, EN | 1 |
| Ahn, SH; Baek, YH; Chang, Y; Choe, WH; Jang, JW; Jang, JY; Kim, GA; Kim, HY; Kim, JH; Kim, M; Kim, MA; Kim, SG; Kim, SU; Kim, YJ; Kim, YS; Koh, M; Kwon, JH; Lee, HA; Lee, HW; Lee, JH; Lee, SW; Lee, YS; Lim, YS; Park, Y; Seo, YS; Shim, JJ; Sinn, DH; Yang, H; Yim, HJ; Yoon, JH; Zoulim, F | 1 |
| Azmi, M; Baber, ZU; Badlani, S; Dodani, SK; Nasim, A; Sheerani, M | 1 |
| Abrams, EJ; Bartilol, K; Batuka, J; Gitonga, M; Imbuki, E; Kimani, M; Lahuerta, M; Odhiambo, J; Odhiambo, S; Sugandhi, N; Syowai, M; Vakil, S; Wamicwe, J | 1 |
| He, J; Ma, R; Sun, S; Xu, B; Zhang, Q; Zhang, Y; Zhao, CS | 1 |
| Ahn, SH; Bae, SH; Heo, J; Jang, JY; Kim, CW; Kim, DJ; Kim, IH; Park, JY; Tak, WY; Woo, HY | 1 |
| Acosta, R; Arribas, JR; Brainard, DM; Brinson, C; Clarke, A; Collins, SE; DeJesus, E; Flamm, JA; Gupta, SK; Hagins, D; Huang, H; Maggiolo, F; Martin, H; Martorell, C; Orkin, C; Podzamczer, D; Sax, PE; Stellbrink, HJ; Stephens, JL; Thompson, MA; Wohl, D | 1 |
| Amponsah-Dacosta, E; Blackard, JT; Burnett, RJ; Gededzha, MP; Kyaw, T; Lukhwareni, A; Mphahlele, MJ; Selabe, SG | 1 |
| Chen, H; Hu, XL; Huang, XS; Luo, RH; Shen, XN; Tang, CR; Xiang, SY; Zhang, CT; Zheng, YT | 1 |
| Afolayan, S; Agumah, R; Akang, E; Akanmu, AS; Dosumu, O | 1 |
| Byakika-Kibwika, P; Kalyesubula, R; Nyende, L; Sekasanvu, E | 1 |
| Arribas, JR; Del Amo, J; Díaz, A; Hernán, MA; Jarrín, I; Martínez, E; Moreno, S; Polo, R | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Jang, BK | 1 |
| Chang, SY; Chen, YT; Chen, YW; Huang, CK; Huang, SH; Huang, WC; Hung, CC; Lin, SW; Liu, WC; Ou, ST; Sun, HY | 1 |
| Bajpai, L; Bhutani, H; Jayaraman, K; Kumar, GS; Kurmi, M; Natarajan, S | 1 |
| Cai, WP; Deng, XZ; Hu, FY; Lan, Y; Li, F; Li, LH; Nie, Y | 1 |
| Alhassan, Y; Kambugu, A; Khoo, S; Lamorde, M; Malaba, T; Myer, L; Orrell, C; Reynolds, H; Taegtmeyer, M; Twimukye, A; Waitt, C | 1 |
| Adams-Huet, B; Bedimo, RJ; Maalouf, NM; Moore-Matthews, D; Nguyen, V; Poindexter, J | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Kandala, B; Vaddady, P; Yee, KL | 1 |
| Chan, HLY; Gaggar, A; Ganova-Raeva, L; Khudyakov, Y; Kitrinos, K; Lara, J; Thai, H; Xia, GL; Xu, X | 1 |
| Barbini, B; Campbell, L; Gilleece, Y; Hamzah, L; Ibrahim, F; Kegg, S; Post, FA; Samarawickrama, A; Vincent, R; Waters, L | 1 |
| Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK | 1 |
| Baeten, JM; Haberer, JE; Hodges-Mameletzis, I; Mujugira, A | 1 |
| Acosta, S; Balogun, K; Guzman Lenis, MS; Mount, HT; Sarkar, A; Serghides, L | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Shen, M; Sun, X; Wang, B; Wang, C; Xu, H; Yang, X; Zhu, K | 1 |
| Enomoto, M; Kawada, N; Nishiguchi, S; Tamori, A; Yoshida, K | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
| Ait-Khaled, M; Ajana, F; Jones, B; Nascimento, MC; Santos, J; Scholten, S; Smith, DE; Tenorio, AR; van Wyk, J; Wohlfeiler, M; Wright, J; Wynne, B | 1 |
| Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ | 1 |
| Bhan, AK; Chung, RT; Ghany, MG; Hinerman, AS; Jain, MK; Khalili, M; King, WC; Kleiner, DE; Lisker-Melman, M; Sterling, RK; Sulkowski, M; Wahed, AS; Wong, DK | 1 |
| Alegete, P; Kancherla, P; Kokkirala, TK; Suryakala, D | 1 |
| Cassidy, T; Flowers, T; Gcwabe, Z; Goemaere, E; Goliath, R; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Sayed, K; Schutz, C; Simmons, B; van Zyl, G; Wiesner, L; Zhao, Y | 1 |
| de Carvalho Santana, R; de Lourdes Candolo Martinelli, A; Dessordi, R; Guimarães, MP; Navarro, AM; Romão, EA; Watanabe, LM | 1 |
| Godela, R; Gummadi, S | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Zvada, S | 1 |
| Marukutira, T; Wood, BR | 1 |
| Baxi, SM; Choden, T; Desai, M; Dorjee, K; Hubbard, AE; Reingold, AL | 1 |
| Chen, WC; Cheng, JS; Kao, SS; Li, YD; Li, YR; Lin, HS; Lu, CM; Sun, WC; Tsai, TJ; Tsai, WL; Tsay, FW; Wang, HM; Yin, CH | 1 |
| Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI | 1 |
| Dodda, S; Gangarapu, K; Veerareddy, V | 1 |
| Barbini, B; Campbell, L; Fox, J; Gilleece, Y; Ibrahim, F; Orkin, C; Post, FA; Samarawickrama, A; Tariq, S; Waters, L | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
| Bowen, N; Inzaule, SC; Jordan, MR; Kiiru, JN; Kingwara, L; Momanyi, L; Ngugi, C; Nyanya, W; Oramisi, V | 1 |
| Chen, P; Deng, L; Hong, Z; Li, C; Luo, X; Xia, J; Zheng, X; Zhou, L; Zhou, Y | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Alcaraz, A; Alejos, B; Alonso Socas, MDM; Belza, MJ; Espacio, R; Garaialde, A; García-Yubero, C; Gómez-Ayerbe, C; Gutiérrez Cuéllar, I; Hernández, J; Jarrín, I; Martínez Madrid, OJ; Muñoz Sánchez, J; Olalla, J; Pierola Ruiz de Galarreta, B; Ruiz-Algueró, M; Suárez-García, I | 1 |
| Egger, M; Goldstein, F; Hauser, A; Kouyos, RD; Reichmuth, ML; Riou, J; Wandeler, G | 1 |
| Fidler, S; Fox, J; Kulasegaram, R; Lee, MJ; Nori, A; Smith, C | 1 |
| Alemika, ET; Etuh, MA; Gyang, SS; Iorjiim, WM; Omale, S; Ubani, A | 1 |
| Ake, JA; Bahemana, E; Chang, D; Crowell, TA; Dear, NF; Esber, AL; Iroezindu, M; Kibuuka, H; Maswai, J; Owuoth, J; Polyak, CS; Singoei, V | 1 |
| Blanco, JR; Calzado Isbert, S; López Cortés, LF; Martínez-Sanz, J; Mena, Á; Moreno, E; Moreno, S; Muriel, A; Pineda, JA; Ron, R; Sánchez-Conde, M; Serrano-Villar, S | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Bhattacharya, D; Butler, K; Chakhtoura, N; Currier, JS; Dula, D; Fowler, MG; George, K; Govender, V; Kiweewa, FM; Mohtashemi, N; Moodley, D; Musoke, P; Peters, MG; Ship, H; Tierney, C; Vhembo, T | 1 |
| Afonso Reis, E; Almeida-Brasil, CC; Ceccato, MDGB; de Oliveira Costa, J; Rodrigues, VA; Silveira, MR | 1 |
| Aceiton, J; Bruguera, A; Casabona, J; Deig, E; Díaz, Y; Domingo, P; Imaz, A; Llibre, JM; Miro, JM; Moreno, S; Navarro, G; Navarro, J; Nomah, DK; Reyes-Urueña, J; Vivanco-Hidalgo, RM | 1 |
| Amstutz, A; Belus, JM; Brown, JA; Glass, TR; Klimkait, T; Labhardt, ND; Mokhele, K; Muhairwe, J; Nsakala, BL; Rakuoane, I; Tschumi, N | 1 |
| Aoun-Barakat, L; Cartwright, EJ; Casas, JP; Dickerman, BA; Hernán, MA; Justice, AC; Li, G; Lodi, S; Logan, RW; Park, LS; Rentsch, CT | 1 |
| Evans, D; Hans, L; Levin, L; Steegen, K; Technau, KG | 1 |
| Alhassan, Y; Bokako, S; Burger, D; Byamugisha, J; Byrne, K; Chen, T; Chiong, J; Colbers, A; Hodel, EM; Hu, NC; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Mrubata, M; Myer, L; Nakatudde, I; Orrell, C; Read, J; Read, L; Reynolds, H; Seden, K; Stemmet, LA; Taegtmeyer, M; Theunissen, H; Twimukye, A; Waitt, C; Wang, D | 1 |
| Abdi, B; Bitilinyu-Bangoh, JE; Calvez, V; Descamps, D; Jahn, A; Kalua, T; Lê, MP; Marcelin, AG; Nicholas, S; Ousley, J; Peytavin, G; Schramm, B; Storto, A; Szumilin, E; Temfack, E | 1 |
| Figueredo, CC; Gomes, MP; Juneau, P; Kitamura, RSA; Kubis, GC; Navarro-Silva, MA; Nogueira, KDS; Vieira, F | 1 |
| Katzenstein, D; Kouamou, V; Machekano, R; Manasa, J; Mapangisana, T; Maposhere, C; McCarty, K; Munyati, S; Mutsvangwa, J; Shamu, T | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y | 1 |
| Allahna, E; Christina S, P; Emmanuel, B; Hannah, K; John, O; Jonah, M; Joseph S, C; Julie A, A; Michael, I; Neha, S; Nicole, D; Trevor A, C; Valentine, S | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA; Ajeigbe, AK; Ajose, AO; Akande, AA; Fawale, MB; Jeje, OA; Okesina, BA; Smith, OS | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Cai, L; Guo, Z; He, S; Wang, Y; Wang, Z; Yan, D; Yang, X; Zheng, Y | 1 |
| Abdusalaamu, K; Boulware, DR; Collins, L; Lukande, R; Meya, DB; Mishra, U; Namuju, OC; Nicol, MR; Pastick, KA; Wang, F | 1 |
| Chen, T; Gui, F; Tan, J; Wei, G; Yang, J; Zhao, Y | 1 |
| Baxter, C; Beyer, A; Derkach, E; Lobodina, A; Pyadushkina, E; Rozenberg, V; Ugrekhelidze, D | 1 |
| Aurpibul, L; Best, BM; Campbell, H; Cassim, H; Cooper, E; Flynn, P; Gray, KP; Krotje, C; McCarthy, K; McFarland, E; Melvin, AJ; Moye, J; Ounchanum, P; Rungmaitree, S; Scheckter, R; Teppler, H; Tobin, NH; Townley, E; Wan, H; Yedla, M; Yee, KL | 1 |
| Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H | 1 |
| Derkach, EV; Pyadushkina, EA | 1 |
| Arribas, JR; Cabello, A; Curran, A; de la Cámara, SP; Del Amo, J; Díaz, A; Dueñas, C; Hernán, MA; Iribarren, JA; Jarrín, I; Macías, J; Mariño, AI; Martínez, E; Montero, M; Moreno, S; Polo, R | 1 |
| Andreoni, M; Barchi, V; De Simone, G; Iannazzo, R; Iannetta, M; Massa, B; Rindi, LV; Sarmati, L | 1 |
| Bhrusundi, M; Dravid, A; K R, R; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; S, A | 1 |
| Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF | 1 |
| Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y | 1 |
| Aristegui, I; Cahn, P; Cardozo, N; Cesar, C; Figueroa, MI; Fink, V; Frola, CE; Gun, A; Patterson, P; Radusky, PD; Sued, O; Zalazar, V | 1 |
| Abba, A; Beloumou, GA; Billong, SC; Bouba, NP; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa Ndjeyep, SC; Eben-Moussi, E; Etame, NK; Fokam, J; Ka'e, AC; Kengni, AMN; Kouanfack, C; Meledie, AP; Molimbou, E; Mossiang, L; Ndjolo, A; Nka, AD; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Teto, G; Tommo Tchouaket, MC; Yagai, B; Zoung-Kanyi Bissek, AC | 1 |
| Cassidy, T; Flowers, T; Goemaere, E; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Omar, Z; Sayed, K; Van Zyl, G; Zhao, Y | 1 |
| Ake, JA; Bahemana, E; Cavanaugh, JS; Crowell, TA; Dear, N; Esber, AL; Ganesan, K; Iroezindu, M; Kibuuka, H; Maswai, J; Mwesigwa, R; Owuoth, J; Parikh, AP; Polyak, CS; Reed, D; Shah, N; Singoei, V | 1 |
| Mohamed, TALH; Navabshan, I; Ramamurthy, VA; Thangaraju, P; Yella, SST | 1 |
| Fan, X; Huang, H; Jiao, Y; Li, J; Wang, FS; Yu, XD; Zhang, D | 1 |
| Nguyen, TK; Van Le, D | 1 |
| Guan, W; Li, T; Li, Y; Lin, Q; Song, X; Xu, Y; Yu, W; Zhang, Y; Zhang, Z | 1 |
| Hao, X; Li, B; Li, L; Ni, J; Tian, Z; Wu, L; Xiao, Y; Zhang, W; Zhao, D; Zhao, X | 1 |
| Caldeira, DB; Camargo, M; de Lima, IB; Dias, D; Diaz, RS; Galinskas, J; Hunter, JR; Nassar, I; Schechter, M; Sucupira, MC | 1 |
| Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Fang, Z; Gang, X; Guoqiang, Z; Jing, C; Min, W; Ning, W; Wei, T; Xingzhi, W | 1 |
| Hachey, D; Shiluama, R; Singu, BS; van Woerden, I | 1 |
| Ambe Chenwi, C; Billong, SC; Bouba, Y; Colizzi, V; Ebiama Lifanda, L; Efakika Gabisa, J; Fainguem, N; Flore Yimga, J; Fokam, J; Hadja, H; Halle, EG; Ka'e, AC; Kamgaing, N; Kembou, E; Kengni Ngueko, AM; Kesseng, D; Ketchaji, A; Mamgue Dzukam, FY; Moudourou, S; Nayang Mundo, RA; Ndiang Tetang, S; Ndjolo, A; Ndombo Koki, P; Ngoufack Jagni Semengue, E; Njom-Nlend, AE; Nka, AD; Nnomo Zam, MK; Pabo, W; Pamen, B; Perno, CF; Saounde Temgoua, E; Simo Kamgaing, R; Sosso, SM; Takou, D; Tangimpundu, C; Tommo Tchouaket, MC; Zoung-Kanyi Bissek, AC | 1 |
| Arai, K; Hayakawa, N; Honda, M; Horii, R; Kagaya, T; Kaneko, S; Kawaguchi, K; Komura, T; Mizukoshi, E; Nio, K; Nishikawa, M; Orita, N; Sakai, Y; Shimakami, T; Shimode, T; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Avedissian, SN; Fletcher, CV; Mykris, TM; Podany, AT; Scarsi, KK; Weinhold, J; Winchester, LC | 1 |
| Amole, C; Jenkins, SY; Panos, Z; Resar, D; Ripin, D; Staple, A; Watkins, M | 1 |
| Burger, D; Chen, RQ; Colbers, A; Geerlings, S; Zino, L | 1 |
| Ajeh, R; Beloumou, G; Bouba, NP; Cappelli, G; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa, S; Fokam, J; Kembou, E; Mbanya, D; Ndjolo, A; Perno, CF; Santoro, MM; Semengue, ENJ; Takou, D; Tala, V; Teto, G | 1 |
| Collier, AC; Delle Fratte, R; Eguchi, M; Ho, RJY; Melvin, AJ; Perazzolo, S; Stephen, ZR; Xu, X | 1 |
| Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N | 1 |
| Mhembere, T; Stranix-Chibanda, L | 1 |
| Bansi-Matharu, L; Cambiano, V; Cowan, F; Ehrenkranz, P; Gilks, CF; Godfrey, C; Hargreaves, JR; Lundgren, JD; Phillips, AN; Revill, P; Rodger, A; Shahmanesh, M; Sibanda, E; Sikwese, K; Smith, J | 1 |
| Buteaue, J; Dos Santos, G; Duval, N; Francois, K; Geffrard, H; Giron, A; Inzaule, SC; Jordan, MR; Journel, I; Pierre, E; Sued, O; Van Onacker, JD | 1 |
| Kouamou, V; Manasa, J; Ndhlovu, CE; Washaya, T | 1 |
| Alagaratnam, J; Ambrosioni, J; Bamford, A; Boesecke, C; Calmy, A; Cinque, P; Guaraldi, G; Koval, A; Levi, L; Martínez, E; Marzolini, C; Mastrangelo, A; Mendao, L; Molina, JM; Oprea, C; Rockstroh, JK; Van Bremen, K; Waalewijn, H; Welch, S; Winston, A | 1 |
| Ait-Khaled, M; Espinosa, N; Fernvik, E; Grove, R; Gulminetti, R; Hagins, D; Man, C; Sierra Madero, J; Sievers, J; Tsai, HC; van Wyk, J; Wynne, B; Zolopa, A | 1 |
| Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B | 1 |
| Chinula, L; Corbett, AH; Cottrell, ML; Gajer, P; Haddad, LB; Hurst, S; Kourtis, AP; Lantz, AM; Nelson, JAE; Nicol, MR; Ravel, J; Tang, JH; Tegha, G | 1 |
| Cai, W; Gu, F; Guo, P; He, Y; Hu, F; Lan, Y; Li, H; Li, L; Li, Y; Lin, W; Tang, X; Zhong, H | 1 |
| Chandiwana, P; Duri, K; Gumbo, FZ; Marere, T; Mataramvura, H; Mazengera, LR; Mazhandu, AJ; Munjoma, PT | 1 |
| Beghetto, B; Borella, R; Borghi, V; Cossarizza, A; Cozzi-Lepri, A; Cuomo, G; De Biasi, S; Digaetano, M; Fidanza, L; Gibellini, L; Guaraldi, G; Mattioli, M; Menozzi, M; Milic, J; Mussini, C; Nardini, G; Neroni, A; Orlando, G; Paolini, A; Roncaglia, E; Tartaro, DL | 1 |
| Anuradha, S; Bhrusundi, M; Dravid, AN; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; Raveendra, KR | 1 |
96 review(s) available for tenofovir and lamivudine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Infectious Disease Transmission, Professional-to-Patient; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Physicians; Risk Factors; Risk Management; Tenofovir; Viral Load | 2003 |
Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Emtricitabine; Famciclovir; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Organophosphorus Compounds; Polyethylene Glycols; Prodrugs; Prognosis; Recombinant Proteins; Tenofovir; Zalcitabine | 2004 |
New treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Sulfonamides; Tenofovir; Zidovudine | 2005 |
[Liver transplantation for complications of hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Mutation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Vaccination; Viral Load; Virus Replication | 2006 |
Personal view: the management of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Tenofovir | 2006 |
Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Nucleosides; Nucleotides; Organophosphonates; Recurrence; Tenofovir | 2006 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Guanine; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Preventive Medicine; Tenofovir | 2006 |
Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
[Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Viral; Hepatitis B; Hepatitis B Surface Antigens; HIV Seropositivity; Humans; Lamivudine; Middle Aged; Organophosphonates; Tenofovir | 2007 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2007 |
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2007 |
Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2007 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
Hepatitis B and liver transplantation: 2008 update.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B Vaccines; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2009 |
[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Multicenter Studies as Topic; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2008 |
[Resistance in hepatitis B virus].
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, pol; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Molecular; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Virus Replication | 2008 |
[Clinical management of patients with chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Biopsy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Liver Transplantation; Male; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2008 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2009 |
Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Graft Survival; Guanine; Hepatitis B; Humans; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Transplantation; Nucleosides; Nucleotides; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome | 2009 |
[Chronic hepatitis B: current therapy].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2008 |
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Regression Analysis; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
Topics: Adenine; Adjuvants, Immunologic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Risk Assessment; Serologic Tests; Severity of Illness Index; Tenofovir; Treatment Outcome | 2010 |
Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.
Topics: Adenine; Antiviral Agents; Asia; Guanine; Hepatitis B; Hepatitis B virus; Humans; Interferons; Lamivudine; Liver Transplantation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Organophosphonates; Quality of Life; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United Kingdom | 2010 |
On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
Topics: Adenine; Antiviral Agents; Asia; Biomarkers; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2010 |
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2010 |
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2010 |
Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Female; Greece; Hepatitis B; Hepatitis C; Humans; Inflammatory Bowel Diseases; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Retrospective Studies; Ribavirin; Tenofovir; Treatment Outcome | 2010 |
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Hepatitis B virus resistance to antiviral drugs: where are we going?
Topics: Adenine; Antiviral Agents; Capsid; Clinical Protocols; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Internalization; Virus Replication | 2011 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Interferons; Lamivudine; Liver Failure, Acute; Organophosphonates; Tenofovir | 2012 |
[Pharmacological treatment of acute hepatitis B].
Topics: Acute Disease; Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Spain; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2012 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load | 2012 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load; World Health Organization | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Topics: Adenine; Age Factors; Antiviral Agents; Comorbidity; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Life Style; Organophosphonates; Severity of Illness Index; Telbivudine; Tenofovir; Thymidine; Time Factors | 2012 |
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Mutation; Nucleosides; Nucleotides; Organophosphonates; Prognosis; Tenofovir; Viral Load | 2012 |
[Interdisciplinary aspects of and new drugs for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Gastroenterology; Guanine; Hematology; Hepatitis B, Chronic; Humans; Hungary; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Interdisciplinary Communication; Interferons; Lamivudine; Medical Oncology; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rheumatology; Tenofovir | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir | 2013 |
[Reactivation of chronic hepatitis B].
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Biomarkers; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Inflammation; Lamivudine; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2013 |
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Renal Insufficiency, Chronic; Telbivudine; Tenofovir; Thymidine | 2014 |
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2014 |
HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Sex Factors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2014 |
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Tenofovir | 2014 |
New therapeutic perspectives in HBV: when to stop NAs.
Topics: Adenine; Algorithms; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2014 |
Management of chronic hepatitis B in children: an unresolved issue.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic; Guanine; Hepatitis B, Chronic; Humans; Immune Tolerance; Incidence; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Risk; Tenofovir | 2014 |
Molecular diagnosis and treatment of drug-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Diagnostic Techniques; Mutation; Nucleic Acid Hybridization; Organophosphonates; Phenotype; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir; Treatment Outcome | 2014 |
Virological efficacy of abacavir: systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2014 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence.
Topics: Adenine; Anti-HIV Agents; Breast Feeding; Disease Transmission, Infectious; Female; Hepatitis B; Humans; Infant, Newborn; Lamivudine; Organophosphonates; Pregnancy; Tenofovir | 2015 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Tenofovir | 2016 |
Combination antiretroviral studies for patients with primary biliary cirrhosis.
Topics: Animals; Anti-Retroviral Agents; Betaretrovirus; Clinical Trials as Topic; Drug Therapy, Combination; Emtricitabine; Humans; Lamivudine; Liver Cirrhosis, Biliary; Lopinavir; Mammary Tumor Virus, Mouse; Mice; Tenofovir; Zidovudine | 2016 |
Care of Patients With HIV Infection: Antiretroviral Drug Regimens.
Topics: Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
Topics: Adenine; Alanine Transaminase; Antigens, Viral; Antiviral Agents; Child; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Interferon-alpha; Lamivudine; Molecular Targeted Therapy; Organophosphonates; Practice Guidelines as Topic; Seroconversion; Telbivudine; Tenofovir; Thymidine; Viral Envelope Proteins | 2017 |
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Antiviral therapies for managing viral hepatitis in lymphoma patients.
Topics: Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis C; Humans; Lamivudine; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab; Tenofovir; Virus Activation | 2017 |
Management of Antiviral Resistance in Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2017 |
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Organophosphonates; Survival Analysis; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Activation | 2017 |
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates; Retrospective Studies; Survival Analysis; Telbivudine; Tenofovir; Thymidine | 2017 |
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleic Acid Synthesis Inhibitors; Organophosphonates; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Viral Load | 2017 |
Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2017 |
The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir | 2018 |
Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis.
Topics: Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Doravirine: First Global Approval.
Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles | 2018 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Network Meta-Analysis; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Community and activists demand for tenofovir/emtricitabine or lamivudine/dolutegravir and routine viral load testing.
Topics: Anti-HIV Agents; Drug Monitoring; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Residence Characteristics; Tenofovir; Viral Load | 2019 |
Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Topics: Adenine; Antiviral Agents; Bayes Theorem; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Network Meta-Analysis; Organophosphonates; Prospective Studies; Telbivudine; Tenofovir | 2019 |
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2020 |
Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.
Topics: Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Randomized Controlled Trials as Topic; Seroconversion; Tenofovir; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.
Topics: Administration, Oral; Anti-HIV Agents; HIV Infections; Homosexuality; Humans; Lamivudine; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reproducibility of Results; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
Topics: Adult; Anti-Retroviral Agents; Bayes Theorem; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Tenofovir; Viral Load; Zidovudine | 2022 |
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
171 trial(s) available for tenofovir and lamivudine
| Article | Year |
|---|---|
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Tenofovir; Time Factors; Viral Load | 2002 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2003 |
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Prospective Studies; Stavudine; Tenofovir; Viral Load | 2004 |
Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Oxazines; Tenofovir; Zidovudine | 2004 |
Tenofovir regimen compared with Combivir.
Topics: Adenine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Maximum Tolerated Dose; Organophosphonates; Risk Assessment; Severity of Illness Index; Single-Blind Method; Tenofovir; Treatment Outcome; United States; Viral Load; Zidovudine | 2005 |
Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Models, Biological; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2005 |
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Topics: Adenine; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Sequence Analysis, Protein; Tenofovir; Treatment Failure; Viral Load | 2005 |
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Time Factors; Treatment Failure | 2005 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Countries; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome; Uganda; Viral Load; Zidovudine; Zimbabwe | 2006 |
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome | 2006 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Tenofovir; Treatment Failure | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Oxazines; RNA, Viral; Tenofovir; Time Factors; Viral Load; Zidovudine | 2006 |
Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Viral Load; Zidovudine | 2006 |
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2007 |
Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Zidovudine | 2006 |
No change in calculated creatinine clearance after tenofovir initiation among Thai patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Body Weight; Creatinine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Organophosphonates; Tenofovir; Thailand | 2007 |
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexual Partners; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2008 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Latin America; Male; Middle Aged; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Thailand; Time Factors; Treatment Outcome; United States | 2007 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2008 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mitochondrial; HIV Infections; Humans; Lamivudine; Lipids; Liver Function Tests; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Tenofovir; Thailand | 2008 |
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2008 |
Lack of a significant drug interaction between raltegravir and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Endpoint Determination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Spain; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Thailand; Treatment Outcome; Zidovudine | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Nevirapine; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Viral Proteins | 2009 |
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; Lamivudine; Liver; Male; Middle Aged; Models, Biological; Organophosphonates; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2009 |
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Spain; Tenofovir; Treatment Failure; Treatment Outcome | 2009 |
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Raltegravir as effective as efavirenz in 144-week data.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hyperinsulinism; Hyperlipidemias; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Thymidine; Treatment Outcome; Young Adult | 2009 |
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HLA-B Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV Infections; Home Care Services; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Uganda; Zidovudine | 2009 |
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Topics: Adenine; Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fractures, Bone; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Therapeutic Equivalency; Time Factors; Treatment Failure; Viral Load; Young Adult | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; beta 2-Microglobulin; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Middle Aged; Organophosphonates; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Bone and Bones; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2010 |
Selective determination of antiretroviral agents tenofovir, emtricitabine, and lamivudine in human plasma by a LC-MS-MS method for a bioequivalence study in healthy Indian subjects.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chromatography, Liquid; Cross-Over Studies; Deoxycytidine; Drug Stability; Emtricitabine; Humans; India; Lamivudine; Least-Squares Analysis; Male; Middle Aged; Organophosphonates; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir; Therapeutic Equivalency | 2010 |
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Viral; Epidemiologic Methods; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2011 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Urolithiasis | 2011 |
Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Lipid Metabolism; Male; Middle Aged; Organophosphonates; Prospective Studies; Stavudine; Tenofovir; Treatment Outcome | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Quality of Life; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Organophosphonates; Phospholipases A2; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Tenofovir; Vascular Cell Adhesion Molecule-1 | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Glomerulus; Lamivudine; Male; Nevirapine; Organophosphonates; Risk Factors; Tenofovir; Time Factors; Zidovudine | 2011 |
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adipose Tissue; Adult; Biomarkers; Body Fat Distribution; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Extremities; HIV Infections; Humans; Lamivudine; Middle Aged; Organophosphonates; Predictive Value of Tests; Tenofovir | 2011 |
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Developing Countries; Drug Costs; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Bone Density; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2012 |
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black or African American; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sex Factors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Linear Models; Male; Middle Aged; Netherlands; Organophosphonates; Pilot Projects; Research Design; Statistics, Nonparametric; Tenofovir; Treatment Outcome; Zidovudine | 2012 |
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Bone and Bones; Bone Density; Creatinine; Cystatin C; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Osteocalcin; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; C-Reactive Protein; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Inflammation; Interleukin-6; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Topics: Abortion, Spontaneous; Adenine; Adult; Anti-HIV Agents; Body Height; Body Weight; Breast Feeding; Burns; Cause of Death; Child, Preschool; Congenital Abnormalities; Drug Combinations; Female; Follow-Up Studies; Fractures, Bone; Growth; HIV Infections; HIV Seropositivity; Humans; Infant; Infant Mortality; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Measles; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Respiratory Tract Infections; Tenofovir; Uganda; Zidovudine; Zimbabwe | 2012 |
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Absorptiometry, Photon; Adenine; Adult; Bone Density; Bone Remodeling; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Tenofovir | 2012 |
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genome, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2013 |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cognition Disorders; Depression; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2012 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; Genitalia, Female; HIV Infections; Humans; Lamivudine; Models, Biological; Oligopeptides; Organophosphonates; Premenopause; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diet; Drug Administration Schedule; Drug Substitution; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Peripheral Nervous System Diseases; Stavudine; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Drug Tolerance; Female; Genotype; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phenotype; Phosphorus; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2012 |
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Risk; Tenofovir | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Interactions; Emtricitabine; Female; Healthy Volunteers; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nitriles; Organophosphonates; Pyrazoles; Tenofovir; Young Adult; Zidovudine | 2013 |
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Blood Glucose; Body Composition; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Linear Models; Lipids; Longitudinal Studies; Male; Organophosphonates; Stavudine; Tenofovir | 2013 |
Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Evolution, Molecular; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Phylogeny; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Treatment Failure; Young Adult | 2013 |
Variability of raltegravir plasma levels in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2013 |
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone and Bones; Bone Density; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir | 2013 |
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, Viral; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Europe; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; New Zealand; North America; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Risk Factors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding | 2014 |
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Probability; Retrospective Studies; RNA, Viral; Tenofovir; Uganda; Viral Load; Zidovudine | 2014 |
HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adult; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; HLA-DQ Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Radiography; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Point Mutation; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
Topics: Adenine; Adult; Albuminuria; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Linear Models; Male; Organophosphonates; Proteinuria; Tenofovir | 2014 |
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Fat Distribution; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; Tenofovir; Zidovudine | 2015 |
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
Topics: Adult; Alkynes; Benzoxazines; Cholesterol; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lamivudine; Male; Middle Aged; Tenofovir | 2015 |
Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Tenofovir | 2015 |
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aspartate Aminotransferases; Coinfection; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Prospective Studies; Tenofovir; Viral Load | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Raltegravir Potassium; Rifampin; Tenofovir; Tuberculosis | 2015 |
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Ritonavir; South Australia; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Topics: Adult; Anti-HIV Agents; Body Mass Index; Bone Density; Calcitriol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Osteoporosis; Prospective Studies; Tenofovir; Vitamin D | 2016 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Cross-Sectional Studies; Female; Ghana; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load; Viremia; Young Adult | 2016 |
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Resorption; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Plasma; Tenofovir; Vitamin D-Binding Protein; Young Adult | 2016 |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir | 2016 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Patient Safety; Pregnancy; Primary Prevention; RNA, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Viral Load; Zidovudine | 2017 |
Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; RNA, Viral; Self Report; Tenofovir; Treatment Failure; Viral Load | 2017 |
Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Insulin-Like Growth Factor I; Lamivudine; Male; Prospective Studies; Tenofovir; Zidovudine | 2017 |
Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tablets; Tenofovir; Thailand | 2017 |
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Elasticity Imaging Techniques; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Raltegravir Potassium; Tenofovir; Triglycerides; Waist-Hip Ratio | 2017 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
Tenofovir
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hospital Costs; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2017 |
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognition; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Prospective Studies; Ritonavir; Tenofovir | 2019 |
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Equivalence Trials as Topic; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; Pyridones; Quinolones; Ritonavir; Tenofovir; Treatment Outcome; Triazoles; Young Adult | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2019 |
[Effectiveness and safety of generic version of lamivudine/tenofovir and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2012-2014].
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Colombia; Cyclopropanes; Drugs, Generic; Female; Humans; Lamivudine; Male; Prospective Studies; Reproducibility of Results; Statistics, Nonparametric; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2019 |
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain | 2019 |
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Triazoles | 2019 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Ultrasonography, Prenatal; Young Adult; Zidovudine | 2019 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Young Adult | 2020 |
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
Topics: Adenine; Adiposity; Antiviral Agents; Cross-Sectional Studies; DNA, Mitochondrial; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Organophosphonates; RNA, Mitochondrial; Tenofovir | 2020 |
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Biological Availability; Cross-Over Studies; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles; Young Adult | 2020 |
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Sustained Virologic Response; Telbivudine; Tenofovir | 2020 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Kidney; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Insulin Resistance; Lamivudine; Lipids; Metabolic Syndrome; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Weight Gain | 2021 |
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2021 |
Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use.
Topics: Absorptiometry, Photon; Adult; Anti-Retroviral Agents; Body Composition; Bone Density; Bone Resorption; Cross-Sectional Studies; Female; Femur Neck; Fibroblast Growth Factor-23; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hip; Humans; Lamivudine; Lumbar Vertebrae; Male; Middle Aged; Osteoclasts; Tenofovir | 2021 |
Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe.
Topics: Adolescent; Anti-Retroviral Agents; Atazanavir Sulfate; Caregivers; Female; Hair; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Models, Biological; Overweight; Ritonavir; Tenofovir; Thinness; Viral Load; Zimbabwe | 2021 |
Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir; Treatment Outcome | 2022 |
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Topics: Adenosine Monophosphate; Adult; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Healthy Volunteers; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Tenofovir; Uganda | 2021 |
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Middle Aged; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Oxazines; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B e Antigens; HIV Infections; Humans; Infant, Newborn; Lamivudine; Pregnancy; Pregnancy Outcome; Tenofovir; Zidovudine | 2022 |
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Oxazines; Piperazines; Postpartum Period; Pregnancy; Pyridones; Tenofovir; Viral Load | 2022 |
Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Protease Inhibitors; Tenofovir; Viral Load; Young Adult; Zimbabwe | 2022 |
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles | 2022 |
Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial.
Topics: Adult; HIV Infections; HIV-1; Humans; India; Lamivudine; Tenofovir | 2022 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Topics: Adult; Anti-Retroviral Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; RNA; Tenofovir | 2023 |
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
Topics: Adult; Anti-Retroviral Agents; Argentina; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Transgender Persons | 2023 |
No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Anti-HIV Agents; Cohort Studies; Drug Interactions; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Isoniazid; Lamivudine; Rifampin; RNA; South Africa; Tenofovir; Tuberculosis; Viral Load | 2023 |
Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC
Topics: CD4-CD8 Ratio; HIV Infections; Humans; Interleukin-6; Lamivudine; Tenofovir | 2023 |
Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir; Treatment Outcome; Viral Load | 2023 |
538 other study(ies) available for tenofovir and lamivudine
| Article | Year |
|---|---|
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Cell Line; Dogs; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors | 2007 |
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidine Nucleosides; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2007 |
Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
Topics: Adenine; Amino Acid Sequence; Animals; Antiviral Agents; Catalysis; Cell Line; Dose-Response Relationship, Drug; Endogenous Retroviruses; HIV-1; Humans; Kidney; Molecular Sequence Data; Organophosphonates; Polymerase Chain Reaction; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Stavudine; Swine; Swine, Miniature; Tenofovir; Virus Replication; Zidovudine | 2007 |
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2007 |
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
Topics: Anti-HIV Agents; HeLa Cells; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zidovudine | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Nitriles; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors | 2009 |
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fetal Blood; Genitalia, Female; HIV-1; Humans; Hydrocortisone; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication.
Topics: Adenosine; Amides; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatitis B virus; HIV-1; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Conformation; Organophosphonates; Prodrugs; Structure-Activity Relationship; Virus Replication | 2016 |
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
Topics: Administration, Oral; Animals; Antiviral Agents; Capsid; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Viral; Hep G2 Cells; Hepatitis B virus; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2017 |
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Aspartic Acid; Cell Line; Cytomegalovirus; Drug Resistance, Viral; Drug Stability; Esters; Hepatitis B virus; Herpesvirus 3, Human; Humans; Hydrogen-Ion Concentration; Microsomes, Liver; Nucleosides; Organophosphonates; Prodrugs; Stereoisomerism; Structure-Activity Relationship | 2017 |
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
Topics: | 2019 |
Discovery of (1
Topics: Animals; Antiviral Agents; Binding Sites; Capsid; Capsid Proteins; Cell Line; DNA, Viral; Drug Design; Drug Resistance, Viral; Hepatitis B virus; Humans; Mice; Microsomes, Liver; Protein Structure, Tertiary; Pyrazoles; Pyridines; Solubility; Structure-Activity Relationship; Sulfonamides; Virus Assembly; Virus Replication | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture.
Topics: Acyclovir; Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir; Tumor Cells, Cultured | 2000 |
Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
Topics: Adenine; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Drug Therapy; Epoetin Alfa; Erythropoietin; Hepatitis C; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Recombinant Proteins; Saquinavir; Tenofovir; Zidovudine | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Editorial comment: a tale of two viruses.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells.
Topics: Adenine; Anti-HIV Agents; Cell Line; Cells, Cultured; Dendritic Cells; Humans; Lamivudine; Langerhans Cells; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; T-Lymphocytes; Tenofovir; Zidovudine | 2002 |
Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.
Topics: Adenine; Base Sequence; Cell Line; DNA Primers; Drug Resistance, Viral; Lamivudine; Mutagenesis, Site-Directed; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Simian Immunodeficiency Virus; Tenofovir | 2003 |
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
Topics: Adenine; Antiviral Agents; Drug Resistance, Microbial; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Virus Activation | 2003 |
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Topics: Adenine; Anti-HIV Agents; Cell Line; Cytidine Triphosphate; Didanosine; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Transfection; Zalcitabine; Zidovudine | 2003 |
Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Cell Line; Dideoxynucleosides; Human T-lymphotropic virus 1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Virus Replication; Zalcitabine; Zidovudine | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Warning issued on non-response rates.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Studies of molecular mechanism of tenofovir against 3TC- and AZT-resistance mutant HIV-1 reverse transcriptase.
Topics: Adenine; Amino Acid Sequence; Drug Resistance, Viral; HIV Reverse Transcriptase; Humans; Lamivudine; Models, Molecular; Mutagenesis, Site-Directed; Organophosphonates; Organophosphorus Compounds; Protein Conformation; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2003 |
Triple combinations regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Oxazines; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Topics: Adenine; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Failure of combination abacavir + tenofovir + lamivudine (3TC).
Topics: Adenine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Early nonresponse for tenofovir regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2003 |
Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
High rate of virologic failure with once-daily ddI/3TC/TDF.
Topics: Adenine; Didanosine; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
[Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Humans; Lamivudine; Lipids; Organophosphonates; Organophosphorus Compounds; Oxazines; Stavudine; Tenofovir | 2003 |
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.
Topics: Adenine; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Sampling Studies; Severity of Illness Index; Tenofovir; Treatment Outcome; Viral Load | 2004 |
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
Topics: Adenine; Anti-HIV Agents; Cloning, Molecular; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Genotype; HIV; HIV Reverse Transcriptase; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
EU issues warning about HAART regimen.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; European Union; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pilot Projects; Safety; Tenofovir; Treatment Failure; Viral Load | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2004 |
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cell Line; DNA-Directed DNA Polymerase; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Transfection; Virus Replication | 2004 |
[3 years' data of tenofovir. Confirmed as a valuable building block].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Tenofovir therapy for lamivudine resistance following liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome | 2004 |
Tenofovir use in a patient with a severe renal impairment.
Topics: Adenine; Adult; Diabetic Nephropathies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2004 |
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directed DNA Polymerase; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2004 |
The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Apoptosis; Cell Differentiation; Didanosine; Dideoxynucleosides; HIV-1; HIV-Associated Lipodystrophy Syndrome; Lamivudine; Lipid Metabolism; Mice; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2004 |
Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine.
Topics: Adenine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2005 |
Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2005 |
Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; HIV Infections; Humans; Lamivudine; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Risk-Taking; Stavudine; Tenofovir; Zidovudine | 2005 |
Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Dideoxynucleosides; Drug Combinations; Erythrocyte Indices; Humans; Lamivudine; Organophosphonates; Patient Compliance; Salvage Therapy; Tenofovir; Viral Load; Viremia; Zidovudine | 2005 |
Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
Topics: Adenine; Anti-HIV Agents; Cell Line; Dideoxynucleosides; Drug Interactions; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Organophosphonates; Tenofovir | 2005 |
Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Waiting Lists | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir | 2005 |
Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.
Topics: Adenine; Anti-HIV Agents; Cell Line, Transformed; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Tenofovir | 2005 |
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2005 |
Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir | 2006 |
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2006 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Variant of hepatitis B virus with primary resistance to adefovir.
Topics: Adenine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Viremia | 2006 |
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Viremia; Zidovudine | 2006 |
Investigating new antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Pilot Projects; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Topics: Adenine; Anti-HIV Agents; Cell Line; Cell Line, Tumor; Cells, Cultured; Deoxycytidine; Drug Synergism; Emtricitabine; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Organophosphonates; Reverse Transcriptase Inhibitors; T-Lymphocytes; Tenofovir | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Anti-Retroviral Agents; Bias; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Research Design; Tenofovir; Zidovudine | 2006 |
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
Topics: Adenine; Didanosine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Genetic Variation; Genotype; HIV-1; Humans; Inhibitory Concentration 50; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Tenofovir; Time Factors | 2006 |
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
Topics: Adenine; Adult; Disease Progression; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Gene Products, pol; Genotype; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Virus Replication | 2006 |
Rapid improvement of liver function in a patient with HIV and hepatitis B coinfection treated with lamivudine and tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hepatitis; HIV Infections; Humans; Lamivudine; Liver Function Tests; Organophosphonates; Tenofovir; Zidovudine | 2006 |
Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Female; HTLV-I Infections; Humans; Immunosuppressive Agents; Lamivudine; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Organophosphonates; Prednisone; Radiography; Sjogren's Syndrome; Tenofovir | 2006 |
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Genome, Bacterial; HIV-1; Humans; In Vitro Techniques; Lamivudine; Mutagenesis, Site-Directed; Mutation; Organophosphonates; Selection, Genetic; Sequence Analysis, DNA; Tenofovir | 2006 |
Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Regression Analysis; RNA, Viral; Statistics, Nonparametric; Tenofovir; Treatment Outcome | 2006 |
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides; Drug Resistance, Multiple, Viral; Genotype; Glutamic Acid; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lysine; Mutagenesis, Site-Directed; Organophosphonates; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir; Thymine Nucleotides; Zidovudine | 2007 |
Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Transaminases | 2006 |
Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
Topics: Adenine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2004 |
Visual loss secondary to acquired immunodeficiency virus-related progressive multifocal leukoencephalopathy demonstrating clinical improvement with highly active antiretroviral therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Drug Therapy, Combination; Hemianopsia; Humans; JC Virus; Lamivudine; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Oxazines; Tenofovir; Tomography, X-Ray Computed; Vision Disorders; Visual Fields | 2007 |
Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Humans; Kidney Diseases; Lamivudine; Liver Transplantation; Organophosphonates; Secondary Prevention; Tenofovir | 2007 |
Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir.
Topics: Adenine; Animals; Anti-HIV Agents; Chromatography, High Pressure Liquid; Culture Media; Erythrocytes; Female; HIV-1; Humans; In Vitro Techniques; Indicators and Reagents; Lamivudine; Macrophages; Mice; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2007 |
Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?
Topics: Adenine; Adult; Drug Resistance, Multiple, Viral; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
Topics: Adenine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2007 |
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Erythrocytes; HIV Infections; Humans; Lamivudine; Nucleosides; Organophosphonates; Phosphorylation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Emtricitabine; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Point Mutation; Reassortant Viruses; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; New York; Occupational Exposure; Occupational Health Services; Organophosphonates; Patient Compliance; Public Health Administration; Retrospective Studies; Risk Factors; Sex Factors; Student Health Services; Tenofovir; Universities; Zidovudine | 2007 |
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Topics: Adenine; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2007 |
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Topics: Adenine; DNA Repair; Drug Resistance, Multiple, Viral; Genetic Engineering; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Mutation; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 2007 |
Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Organophosphonates; Porphyria Cutanea Tarda; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Health Care Surveys; Hepatitis B Vaccines; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tenofovir; United States | 2007 |
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Carrier State; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; DNA, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; London; Male; Organophosphonates; Prevalence; Tenofovir | 2007 |
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Topics: Adenine; Adult; Arabinofuranosyluracil; Base Sequence; Cell Line, Tumor; Cloning, Molecular; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Viral; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Transfection; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Area Under Curve; Camptothecin; Drug Therapy, Combination; HIV Infections; Humans; Irinotecan; Lamivudine; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Ritonavir; Sarcoma, Kaposi; Tenofovir; White People | 2008 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Development of a novel mouse model to evaluate drug candidates against hepatitis B virus.
Topics: Adenine; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Drug Evaluation, Preclinical; Hepatitis B; Hepatitis B virus; Lamivudine; Mice; Mice, Nude; Organophosphonates; Reproducibility of Results; Tenofovir | 2007 |
Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Deoxyguanine Nucleotides; Dideoxynucleosides; Dideoxynucleotides; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Organophosphonates; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2008 |
Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Thailand; Treatment Outcome | 2007 |
Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of lamivudine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Drug Delivery Systems; Drug Design; Erythrocytes; HIV-1; Humans; In Vitro Techniques; Lamivudine; Macrophages; Organophosphonates; Tenofovir; Virus Replication | 2007 |
Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).
Topics: Adenine; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Sleep Initiation and Maintenance Disorders; Tenofovir | 2008 |
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Boston; Clinical Trials, Phase IV as Topic; Community Health Centers; Deoxycytidine; Disease Transmission, Infectious; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2008 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load; Virus Replication | 2008 |
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
Topics: Adenine; Adult; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Deoxycytidine; Drug Costs; Emtricitabine; Health Care Costs; Health Resources; HIV Infections; HIV-1; Humans; Lamivudine; Models, Economic; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Thymidine; Viral Load; Zidovudine | 2008 |
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Viral Load | 2008 |
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Animals; Antigens, Viral; Antiviral Agents; Deoxycytidine; Disease Models, Animal; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Marmota; Organophosphonates; RNA, Viral; Rodent Diseases; Tenofovir; Virus Replication | 2008 |
CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Humans; Lamivudine; Middle Aged; Organophosphonates; Tenofovir | 2008 |
Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viremia | 2008 |
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir | 2008 |
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Central Nervous System; Cohort Studies; Creatinine; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Retrospective Studies; Risk Factors; RNA, Viral; Tenofovir; Viral Load | 2009 |
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Topics: Adenine; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mutation; Organophosphonates; Promoter Regions, Genetic; Tenofovir | 2008 |
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Topics: Adenine; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Phenotype; Plasmids; Tenofovir; Viral Load | 2009 |
[Protocol for the antiviral therapy of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2008 |
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Mutation, Missense; Nevirapine; Organophosphonates; Plasma; Polymerase Chain Reaction; Selection, Genetic; Tenofovir; Treatment Failure | 2009 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2009 |
Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load | 2009 |
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; Gene Products, pol; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load; Viremia | 2009 |
The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Topics: Adenine; Anti-HIV Agents; Delavirdine; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lamivudine; Microbial Sensitivity Tests; Mutation, Missense; Nevirapine; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2009 |
Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.
Topics: Adenine; Adult; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Genetic Variation; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Proteins | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
Topics: Adenine; Anti-HIV Agents; Cell Line, Tumor; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Lamivudine; Mutation; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Viral Proteins; Virus Replication | 2009 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir | 2009 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; CD4 Lymphocyte Count; Deoxyguanosine; F2-Isoprostanes; Glutathione; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
Topics: Adenine; Administration, Oral; Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Transplantation; Markov Chains; Models, Economic; Organophosphonates; Retrospective Studies; Salvage Therapy; Secondary Prevention; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
FDA approves three generics.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2009 |
Emergency transplantation for acute reactivation of chronic hepatitis B with high viral load: role of antiviral therapy.
Topics: Adenine; Blood Chemical Analysis; DNA, Viral; Hepatitis B; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Secondary Prevention; Tenofovir; Ultrasonography; Viral Load | 2009 |
Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
Topics: Adenine; Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Ribonuclease H, Human Immunodeficiency Virus; Stavudine; Tenofovir | 2009 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Viremia | 2009 |
The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Viremia; Zidovudine | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cell Proliferation; Didanosine; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Interferon-gamma; Killer Cells, Natural; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; T-Lymphocytes; Tenofovir | 2009 |
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Treatment Outcome; Viral Load | 2009 |
On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors.
Topics: Adenine; Chromatography, Ion Exchange; Deoxycytidine; Emtricitabine; Humans; Lamivudine; Leukocytes, Mononuclear; Mass Spectrometry; Organophosphonates; Polyphosphates; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
The art of managing human immunodeficiency virus infection: a balancing act.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2009 |
[The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2009 |
FDA notifications. FDA approves generic combination of efavirenz, lamivudine & tenofovir.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Approval; Drug Combinations; Drugs, Generic; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
Topics: Adenine; Adolescent; Adult; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2010 |
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure; Viremia; Young Adult; Zidovudine | 2010 |
[Protocol for the antiviral therapy of hepatitis B and D].
Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis D; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver Cirrhosis; Nucleotides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2010 |
A controlled trial of initial antiviral regimens for HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Treatment Failure | 2010 |
Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2010 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
Topics: Adenine; Antiviral Agents; Asia; Cost-Benefit Analysis; Decision Support Techniques; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Germany; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Nucleosides; Organophosphonates; Pyrimidinones; Salvage Therapy; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; United States | 2010 |
Viral resistance in hepatitis B: prevalence and management.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genetic Testing; Genotype; Guanine; Hepatitis B; Humans; Lamivudine; Nucleosides; Organophosphonates; Phenotype; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Arabinofuranosyluracil; Cell Line; Cells, Cultured; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatocytes; Humans; Lamivudine; Microbial Sensitivity Tests; Nucleosides; Nucleotides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2010 |
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Genome, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Phenotype; Recombination, Genetic; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2010 |
Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Circular; DNA, Viral; Drug Resistance; Female; Gene Products, pol; Genetic Variation; Genome, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver; Liver Transplantation; Male; Middle Aged; Organophosphonates; Phylogeny; Tenofovir; Trans-Activators; Viral Envelope Proteins; Viral Regulatory and Accessory Proteins; Virus Replication | 2011 |
High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Comorbidity; Cross-Sectional Studies; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Viral Core Proteins; Viral Load; Viral Proteins | 2010 |
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Genotype; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Tenofovir; Time Factors; Viral Load; Zidovudine | 2010 |
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Topics: Adaptation, Biological; Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Tenofovir | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
[Treatment of chronic hepatitis B. High response rate in general practice].
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Germany; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Organophosphonates; Patient Care Team; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2010 |
The impact of gender and anchor drugs on TDF renal toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Lamivudine; Male; Organophosphonates; Sex Factors; Tenofovir | 2010 |
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir; Viral Load; Viral Proteins; Virus Replication | 2011 |
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Young Adult | 2011 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cross-Sectional Studies; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; World Health Organization; Young Adult | 2010 |
Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.
Topics: Adenine; Anti-HIV Agents; DNA-Directed DNA Polymerase; Humans; Lamivudine; Molecular Structure; Organophosphonates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tenofovir; Zidovudine | 2011 |
[Analogs combination therapy in chronic hepatitis B: when and how?].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Topics: Adenine; Antiviral Agents; Combined Modality Therapy; Drug Resistance, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Perioperative Care; Secondary Prevention; Tenofovir; Treatment Outcome | 2011 |
Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome | 2011 |
Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Enzymes; Female; France; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organ Transplantation; Organophosphonates; Pilot Projects; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2011 |
HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-2; Humans; Kidney Failure, Chronic; Lamivudine; Male; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Renal Dialysis; Salvage Therapy; Tenofovir; Treatment Outcome | 2011 |
Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs.
Topics: Adenine; Adult; Elasticity Imaging Techniques; Female; Hepatitis B; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2011 |
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lost to Follow-Up; Male; Medical Audit; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; HIV Seropositivity; Humans; Lamivudine; Longitudinal Studies; Male; Organophosphonates; Parathyroid Hormone; Tenofovir; Vitamin D; Vitamin D Deficiency | 2012 |
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2011 |
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Virus Replication | 2011 |
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection.
Topics: Adenine; Anion Exchange Resins; Antiviral Agents; Calibration; Chromatography, Liquid; Deoxycytidine; Diphosphates; Emtricitabine; Humans; Lamivudine; Leukocytes, Mononuclear; Nucleosides; Organophosphonates; Phosphates; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir; Zidovudine | 2011 |
Battles with donors cloud Malawi's HIV prevention plan.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Charities; Cyclopropanes; Drug Costs; Drug Therapy, Combination; Female; Health Policy; HIV Seropositivity; Humans; Infectious Disease Transmission, Vertical; International Cooperation; Lamivudine; Malawi; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2011 |
Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.
Topics: Adenine; Animals; Antiviral Agents; Biological Availability; Drug Design; Drug Resistance, Viral; Guanine; Hep G2 Cells; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Mice; Models, Chemical; Molecular Structure; Mutation; Organophosphonates; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tenofovir; Tetrazoles | 2011 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2011 |
The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Genotype; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2011 |
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Optimizing initial therapy for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2011 |
Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy.
Topics: Adenine; Adrenal Insufficiency; Adult; Atazanavir Sulfate; Cushing Syndrome; Cytochrome P-450 Enzyme Inhibitors; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Iatrogenic Disease; Injections, Intramuscular; Lamivudine; Oligopeptides; Organophosphonates; Pruritus; Pyridines; Ritonavir; Tenofovir; Triamcinolone Acetonide | 2011 |
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis B, Chronic; Humans; Insurance Coverage; Lamivudine; Liver Cirrhosis; National Health Programs; Organophosphonates; Tenofovir | 2011 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; Glutathione Transferase; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Lamivudine; Male; Middle Aged; Mitochondria; Organophosphonates; Tenofovir; Time Factors | 2012 |
A novel LC-MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study.
Topics: Adenine; Chromatography, High Pressure Liquid; Drug Stability; Humans; Lamivudine; Linear Models; Male; Organophosphonates; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
Hyperhidrosis related to nevirapine therapy.
Topics: Adenine; Aged; Anti-HIV Agents; Drug Eruptions; HIV Seropositivity; Humans; Hyperhidrosis; Lamivudine; Male; Nevirapine; Organophosphonates; Tenofovir | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Guanine; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Hungary; Interferon-alpha; Interferons; Lamivudine; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; France; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Retrospective Studies; RNA, Viral; Selection, Genetic; Tenofovir; Treatment Failure; Viral Load | 2012 |
Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viral Load; Young Adult | 2012 |
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Nucleotides; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome; Young Adult | 2012 |
Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir.
Topics: Adenine; Glomerulonephritis, Membranous; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Current practice of chronic hepatitis B treatment in Southern Italy.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Italy; Lamivudine; Male; Middle Aged; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Patterns, Physicians'; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Young Adult | 2012 |
High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
Topics: Adenine; Adult; Arginine; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Female; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lysine; Male; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; South Africa; Stavudine; Tenofovir; Treatment Failure; Viral Load | 2012 |
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Cells, Cultured; DNA, Viral; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-1; Lamivudine; Organophosphonates; T-Lymphocytes; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study.
Topics: Adenine; Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; Chi-Square Distribution; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Viral Load; Young Adult | 2012 |
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Prescriptions; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Zidovudine | 2012 |
Monitoring of HAART regime antiretrovirals in serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Humans; Lamivudine; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cloning, Molecular; DNA, Viral; Drug Resistance, Viral; Drug Substitution; Escherichia coli; Evolution, Molecular; Female; Follow-Up Studies; Gene Products, pol; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viremia | 2012 |
Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Endothelial Cells; HIV Infections; Humans; Lamivudine; Leukocytes; Organophosphonates; Tenofovir | 2012 |
Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection?
Topics: Acute Disease; Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis D; Hepatitis Delta Virus; Humans; Interferons; Lamivudine; Male; Organophosphonates; RNA, Viral; Superinfection; Tenofovir; Young Adult | 2012 |
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
Topics: Adenine; Anti-HIV Agents; Australia; Biomarkers; Blood Glucose; Body Fat Distribution; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-Associated Lipodystrophy Syndrome; HLA Antigens; HLA-A1 Antigen; HLA-B8 Antigen; HLA-DQ Antigens; Humans; Lamivudine; Linkage Disequilibrium; Male; Middle Aged; Multicenter Studies as Topic; Organophosphonates; Predictive Value of Tests; Randomized Controlled Trials as Topic; Tenofovir; Thymidine | 2012 |
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2013 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Netherlands; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Telbivudine; Tenofovir; Thymidine | 2012 |
Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Italy; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Telbivudine; Tenofovir; Thailand; Thymidine; Travel; Treatment Outcome | 2013 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2013 |
[Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Senegal; Tenofovir; Treatment Outcome | 2013 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult | 2013 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Topics: Adenine; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2013 |
Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
Efficacy of combined antiviral therapy with lamivudine and tenofovir in a liver transplanted girl with de novo hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Transplantation; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-Retroviral Agents; Antibiotic Prophylaxis; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
[Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypertension, Pulmonary; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Tricuspid Valve Insufficiency; Ultrasonography | 2014 |
Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2014 |
Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
Topics: Adenine; Adult; Aged; Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Donor Selection; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Logistic Models; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Time Factors; Tissue Donors; Treatment Outcome; Viral Load | 2013 |
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Disease Management; DNA, Viral; Europe; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtricitabine; Europe; Female; Guideline Adherence; Health Services Accessibility; Hepatitis B; HIV Infections; Humans; Infectious Disease Medicine; Italy; Lamivudine; Male; Multivariate Analysis; Organophosphonates; Practice Guidelines as Topic; Regression Analysis; Tenofovir; Treatment Outcome | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
High throughput LC-MS/MS method for simultaneous determination of tenofovir, lamivudine and nevirapine in human plasma.
Topics: Adenine; Chromatography, High Pressure Liquid; Humans; Lamivudine; Linear Models; Male; Nevirapine; Organophosphonates; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir | 2013 |
Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Immunosuppression Therapy; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Living Donors; Male; Middle Aged; Organophosphonates; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome | 2013 |
Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2013 |
Regression of oral Kaposi's sarcoma after combination antiretroviral therapy.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Humans; Lamivudine; Male; Organophosphonates; Sarcoma, Kaposi; Tenofovir | 2013 |
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Outcome; Zambia | 2013 |
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load | 2013 |
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2014 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Lamivudine; Molecular Sequence Data; Molecular Structure; Organophosphonates; Tenofovir; Thymidine | 2014 |
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Europe; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hospitalization; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Monitoring, Ambulatory; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.
Topics: Adenine; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Follow-Up Studies; Graft Survival; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B virus; Humans; Lamivudine; Liver Transplantation; Markov Chains; Organophosphonates; Prognosis; Quality-Adjusted Life Years; Survival Rate; Tenofovir | 2014 |
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Asian People; Benzoxazines; Biomarkers; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Gene Frequency; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Polymorphism, Single Nucleotide; Prospective Studies; Tenofovir; Young Adult | 2014 |
Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.
Topics: Adenine; Adult; Biomarkers; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Host-Derived Cellular Factors; Humans; Interleukin-10; Lamivudine; Middle Aged; Mutation; Nucleosides; Organophosphonates; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Sex Factors; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tenofovir; Viral Load | 2014 |
Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hep G2 Cells; Hepatitis B virus; Hepatocytes; Humans; Lamivudine; Organophosphonates; Tenofovir; Virus Replication | 2014 |
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Viral Load; Viremia | 2014 |
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Hungary; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2014 |
Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare.
Topics: Adenine; Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Severity of Illness Index; Tenofovir; Time Factors; Young Adult | 2014 |
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Tenofovir; United States | 2014 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemoprevention; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Retrospective Studies; Rural Population; Tenofovir; Young Adult | 2014 |
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Cost-Benefit Analysis; Drugs, Essential; Female; Health Services Research; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir; Thailand; Treatment Outcome | 2014 |
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Creatinine; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Gastrointestinal Diseases; Hepatitis B; Hepatitis B virus; Humans; Incidence; Lamivudine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Organophosphonates; Pyrimidines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2014 |
SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Cell Line; Dideoxynucleotides; Gene Expression; Genes, Reporter; HIV Reverse Transcriptase; HIV-1; Host-Pathogen Interactions; Humans; Lamivudine; Luciferases; Monocytes; Monomeric GTP-Binding Proteins; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Small Interfering; SAM Domain and HD Domain-Containing Protein 1; Stavudine; Tenofovir; Virus Replication; Zidovudine | 2014 |
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
Topics: Adenine; Adult; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Interleukin-10; Interleukin-6; Interleukin-8; Lamivudine; Male; Middle Aged; Organophosphonates; Platelet Activating Factor; Tenofovir; Tumor Necrosis Factor-alpha | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2014 |
Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients.
Topics: Adenine; Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Female; Graft Survival; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Transplantation; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2015 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2014 |
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Professional-to-Patient; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Viral Load; Viremia | 2014 |
Mechanisms of hepatitis B virus resistance development.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2014 |
Hepatitis B virus drug resistance tools: one sequence, two predictions.
Topics: Adenine; Antiviral Agents; Base Sequence; Drug Resistance, Multiple, Viral; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Telbivudine; Tenofovir; Thymidine | 2014 |
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Recurrence; Tenofovir; Withholding Treatment; Young Adult | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleosides; Organophosphonates; Retrospective Studies; Risk Factors; Telbivudine; Tenofovir; Thymidine | 2014 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2015 |
Discovering novel direct acting antiviral agents for HBV using in silico screening.
Topics: Adenine; Albumins; Animals; Antiviral Agents; Binding Sites; Cells, Cultured; Chimera; Databases, Protein; Drug Design; Drug Discovery; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Ligands; Liver; Mice; Middle Aged; Molecular Docking Simulation; Organophosphonates; Protein Binding; Real-Time Polymerase Chain Reaction; Tenofovir | 2015 |
Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Treatment Outcome | 2014 |
Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection.
Topics: Adenine; Animals; Antiviral Agents; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Mice; Organophosphonates; Retrospective Studies; Tenofovir | 2015 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Gene Products, pol; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Organophosphonates; Retrospective Studies; Sequence Analysis, DNA; Tenofovir; Virus Replication | 2015 |
Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Recurrence; Tenofovir | 2015 |
Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; ROC Curve; Tenofovir; Treatment Failure; Treatment Outcome | 2015 |
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Cognition Disorders; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Tenofovir; Tumor Necrosis Factor-alpha; Viral Load | 2015 |
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Apgar Score; Biomarkers; Birth Weight; China; DNA, Viral; Drug Resistance, Viral; Drug Substitution; Female; Genotype; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Live Birth; Male; Middle Aged; Mutation; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Vaccination; Viral Load; Young Adult | 2015 |
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viral Matrix Proteins; Young Adult | 2015 |
[The possibility of tenofovir monotherapy as a rescue therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir; Treatment Outcome | 2015 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Urinalysis; Viral Load | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2015 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Nucleotides; Retrospective Studies; Tenofovir; Treatment Outcome | 2015 |
Efficacy and safety of lamivudine or tenofovir plus intramuscular hepatitis B immunoglobulin in prevention of hepatitis B virus reinfection after liver transplant.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Failure; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Time Factors; Treatment Outcome; Virus Activation; Young Adult | 2015 |
Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Recurrence; Tenofovir | 2015 |
Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Republic of Korea; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2015 |
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retreatment; Tenofovir; Time Factors; Treatment Outcome | 2015 |
Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir; Treatment Failure | 2015 |
Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.
Topics: Adult; Anti-Retroviral Agents; Computer Simulation; Emtricitabine; Female; Humans; Lamivudine; Middle Aged; Models, Biological; Pregnancy; Renal Elimination; Tenofovir; Young Adult | 2015 |
Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Coinfection; Cross-Sectional Studies; Elasticity Imaging Techniques; Female; Ghana; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
Topics: Antiviral Agents; Calibration; Chemistry Techniques, Analytical; Chromatography; Chromatography, High Pressure Liquid; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Nucleosides; Reproducibility of Results; Tandem Mass Spectrometry; Telbivudine; Tenofovir; Thymidine | 2015 |
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Elasticity Imaging Techniques; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Follow-Up Studies; Forecasting; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Italy; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Nucleosides; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; Tenofovir | 2015 |
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Randomized Controlled Trials as Topic; RNA, Viral; Tenofovir; Viremia | 2015 |
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Switzerland; Tenofovir; Viral Load; Young Adult | 2015 |
Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
[Prevention of mother to child transmission of hepatitis B].
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Viral Load; Young Adult | 2015 |
Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Topics: Africa; Antiviral Agents; Biomarkers; Cohort Studies; Coinfection; Drug Therapy, Combination; Emtricitabine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tenofovir; Time Factors | 2016 |
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Models, Molecular; Organophosphonates; Tenofovir; Virus Replication | 2015 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Organophosphonates; Prognosis; Prospective Studies; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Turkey | 2016 |
Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; China; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Ritonavir; RNA, Viral; Rural Population; Tenofovir; Treatment Outcome; Viral Load | 2015 |
COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Government; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Organophosphonates; Real-Time Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load | 2015 |
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Cyclopropanes; Dideoxynucleosides; Drug Combinations; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Lamivudine; Male; Middle Aged; P-Selectin; Tenofovir; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coinfection; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir; Zidovudine | 2015 |
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Quebec; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2015 |
Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(-) donors.
Topics: Adult; Antiviral Agents; Female; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Kidney Transplantation; Lamivudine; Liver; Male; Middle Aged; Postoperative Complications; Tenofovir; Tissue Donors; Transplant Recipients | 2016 |
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Hospitals; Humans; Incidence; Kidney Diseases; Lamivudine; Male; Middle Aged; Nephrons; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Telbivudine; Tenofovir; Thailand; Thymidine; Tropical Medicine | 2015 |
Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tandem Mass Spectrometry; Tenofovir; Viral Load; Young Adult | 2016 |
Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Coinfection; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir | 2016 |
Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2016 |
A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Gene Frequency; Gene-Environment Interaction; Genotype; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nevirapine; Polymorphism, Single Nucleotide; Stavudine; Tenofovir; Thailand | 2016 |
Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Coinfection; Cyclopropanes; Female; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2016 |
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Global Health; HIV Infections; HIV-1; Humans; Lamivudine; Pre-Exposure Prophylaxis; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2016 |
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic st
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Drug Combinations; Drug Monitoring; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lamivudine; Male; Middle Aged; Peroxisome-Targeting Signal 1 Receptor; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2017 |
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine | 2016 |
Stability behaviour of antiretroviral drugs and their combinations. 2: Characterization of interaction products of lamivudine and tenofovir disoproxil fumarate by mass and NMR spectrometry.
Topics: Anti-Retroviral Agents; Drug Compounding; Drug Therapy, Combination; Lamivudine; Magnetic Resonance Spectroscopy; Mass Spectrometry; Tablets; Tenofovir | 2016 |
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney Function Tests; Lamivudine; Liver Function Tests; Male; Middle Aged; Polymerase Chain Reaction; Tenofovir; Treatment Outcome | 2016 |
[Effect of IL-28B polymorphisms on the natural course of HBV infection].
Topics: Adult; Antiviral Agents; Carrier State; Female; Guanine; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Lamivudine; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Real-Time Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine; Turkey | 2016 |
Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
Topics: Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Lamivudine; Male; Propensity Score; Prospective Studies; Risk Assessment; Tenofovir; Treatment Failure; Viral Load | 2016 |
Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.
Topics: Adult; Antiviral Agents; Chemoprevention; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Tenofovir | 2016 |
Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B.
Topics: Adult; Age Factors; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome | 2016 |
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2016 |
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Organophosphonates; Quality-Adjusted Life Years; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Failure; Treatment Outcome | 2016 |
The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunologic Factors; Kaplan-Meier Estimate; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Postoperative Complications; Proportional Hazards Models; Recurrence; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome; Withholding Treatment; Young Adult | 2016 |
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cytotoxins; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Virus Activation; Young Adult | 2016 |
[Efficacy of tenofovir monotherapy or lamivudineadefovir dipivoxil combination therapy in treatment of lamivudine-resistant chronic hepatitis B].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2016 |
Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.
Topics: Adult; Alkaline Phosphatase; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Bone Resorption; Breast Feeding; Collagen Type I; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Male; Peptides; Pregnancy; Tenofovir; Young Adult | 2016 |
Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
Topics: Adult; Antiviral Agents; Drug Monitoring; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons.
Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Models, Statistical; Tenofovir; Therapeutic Equivalency; World Health Organization | 2017 |
Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepatocellular; Culture Media, Conditioned; DNA, Viral; Female; Gene Expression; Genotype; Guanine; Hep G2 Cells; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HT29 Cells; Humans; Interferons; Interleukins; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Polymorphism, Genetic; Recombinant Proteins; Tenofovir; Up-Regulation; Young Adult | 2018 |
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Disclosure; Female; HIV Infections; HIV Seropositivity; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Nevirapine; Retrospective Studies; Tenofovir; Treatment Outcome; Uganda | 2016 |
Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Early Detection of Cancer; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sweden; Tenofovir | 2017 |
Genotoxic and Cytotoxic Effects of Antiretroviral Combinations in Mice Bone Marrow.
Topics: Animals; Antiretroviral Therapy, Highly Active; Bone Marrow; Comet Assay; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Lamivudine; Mice; Micronuclei, Chromosome-Defective; Tenofovir; Zidovudine | 2016 |
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
Topics: Adenine; Adult; Antiviral Agents; Australia; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Topics: Adult; Africa South of the Sahara; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2017 |
Antiretrovirals causing severe pre-eclampsia.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delivery, Obstetric; Female; HIV Infections; Humans; Infant, Extremely Low Birth Weight; Infant, Newborn; Lamivudine; Nevirapine; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Zidovudine | 2016 |
Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.
Topics: Adolescent; Adult; Antiviral Agents; Child; Coinfection; DNA, Viral; Hepatitis B; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Prospective Studies; Tenofovir; Young Adult | 2017 |
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Italy; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Topics: Adult; Coinfection; Drug Combinations; Drug Resistance, Viral; Endemic Diseases; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Tenofovir; Treatment Outcome | 2016 |
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2016 |
Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
Topics: Adenine; Adult; Drug Combinations; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Pilot Projects; Tenofovir | 2016 |
Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; United Kingdom; Viral Load | 2017 |
Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Hospitals; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Retrospective Studies; Rural Population; South Africa; Stavudine; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2016 |
Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Italy; Kaplan-Meier Estimate; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2017 |
HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
Topics: Adult; Amino Acid Substitution; Clonal Evolution; Demography; Epitopes, B-Lymphocyte; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hydrophobic and Hydrophilic Interactions; Lamivudine; Mutation; Protein Domains; Quasispecies; RNA-Directed DNA Polymerase; Tenofovir; Treatment Outcome; Viral Proteins | 2017 |
Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genes, pol; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kenya; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load; Young Adult | 2017 |
Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Topics: Adenine; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Genetic; RNA-Directed DNA Polymerase; Sequence Analysis; Tenofovir; Treatment Failure | 2017 |
The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.
Topics: Bayes Theorem; Darunavir; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Tenofovir | 2017 |
Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Bone Density; Bone Remodeling; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Spain; Tenofovir | 2017 |
Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Lost to Follow-Up; Male; Occupational Exposure; Post-Exposure Prophylaxis; Retrospective Studies; South Africa; Stavudine; Tenofovir; Young Adult; Zidovudine | 2017 |
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation, Missense; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; United States | 2017 |
Stability behavior of antiretroviral drugs and their combinations. 7: Comparative degradation pathways of lamivudine and emtricitabine and explanation to their differential degradation behavior by density functional theory.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Lamivudine; Tenofovir | 2017 |
A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Practice Guidelines as Topic; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Ataxia; Benzoxazines; Brain Diseases; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; South Africa; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Cross-Sectional Studies; Female; Gambia; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Mass Screening; Middle Aged; Practice Guidelines as Topic; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, Liquid; Cohort Studies; Dried Blood Spot Testing; Emtricitabine; Female; Humans; Infant; Lamivudine; Linear Models; Milk, Human; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2017 |
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Lamivudine; Male; Models, Theoretical; Nevirapine; Pregnancy; Retrospective Studies; Stavudine; Tenofovir; Time-to-Treatment; Treatment Failure; Zidovudine | 2017 |
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; ROC Curve; Tenofovir; Treatment Outcome | 2017 |
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lactic Acid; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Prospective Studies; Risk Factors; Sex Factors; Tenofovir; Time Factors; Treatment Outcome; Up-Regulation; Young Adult | 2017 |
Letter: role of tenofovir to prevent mother-to-child transmission of hepatitis B virus.
Topics: Child; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy Complications, Infectious; Tenofovir | 2017 |
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Mozambique; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2017 |
Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Polymerase Chain Reaction; Sensitivity and Specificity; Seroconversion; Tenofovir; Viral Load; Virus Replication | 2017 |
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2017 |
Human immunodeficiency virus infection acquired through a traditional healer's ritual: a case report.
Topics: Adult; Alkynes; Antiviral Agents; Benzoxazines; Ceremonial Behavior; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Lamivudine; Medicine, Traditional; Tanzania; Tenofovir | 2017 |
Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
Topics: Adult; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Republic of Korea; ROC Curve; Severity of Illness Index; Tenofovir; Treatment Outcome | 2018 |
Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Liquid-Liquid Extraction; Medication Adherence; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2018 |
Concomitant AIDS cholangiopathy and Fanconi syndrome as complications of HIV in a single patient.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cholangitis; Fanconi Syndrome; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Tenofovir; Zidovudine | 2017 |
Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Remission Induction; Retrospective Studies; Tenofovir | 2018 |
Antiviral therapy for hepatitis B virus during second pregnancies.
Topics: Adult; Antiviral Agents; Female; Gravidity; Hepatitis B; Hepatitis B virus; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Tenofovir | 2018 |
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Separation; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; T-Lymphocytes; Tenofovir | 2018 |
Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Chromatography, Liquid; Cohort Studies; Emtricitabine; Female; Humans; Infant; Lamivudine; Male; Milk, Human; Mothers; Nigeria; Plasma; Tandem Mass Spectrometry; Tenofovir; Uganda; Young Adult | 2018 |
Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
Topics: Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Cholesterol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Hypertension; Lamivudine; Lipoproteins, LDL; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimester, Third; RNA, Viral; Tenofovir | 2018 |
Utilization of hepatitis B core antibody positive grafts in living donor liver transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Risk; Tenofovir; Transplants; Virus Activation; Young Adult | 2018 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infant, Premature; Infant, Small for Gestational Age; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Rural Population; South Africa; Tenofovir; Young Adult | 2018 |
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
Topics: Animals; Anti-HIV Agents; Drug Carriers; Drug Delivery Systems; Drug Therapy, Combination; HIV Infections; Injections, Subcutaneous; Lamivudine; Leukocytes, Mononuclear; Lopinavir; Lymph Nodes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
Topics: Adult; Africa, Western; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Mutation; Promoter Regions, Genetic; Prospective Studies; Tenofovir | 2018 |
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Disease Transmission, Infectious; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Zidovudine | 2018 |
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Topics: Adult; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies; Tenofovir; Treatment Failure; Viral Load | 2018 |
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2018 |
Changes in Liver Tissue Trace Element Concentrations During Hepatitis B Viral Infection Treatment.
Topics: Adult; Antiviral Agents; Biopsy; Female; Fibrosis; Guanine; Hepatitis B; Humans; Lamivudine; Liver; Liver Function Tests; Male; Middle Aged; Telbivudine; Tenofovir; Trace Elements; Young Adult | 2019 |
Monitoring and treatment results of 88 HBsAg-positive pregnant women.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Tenofovir; Young Adult | 2016 |
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Viremia | 2018 |
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Young Adult | 2019 |
Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Nucleosides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Seroconversion; Tenofovir | 2018 |
Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tenofovir | 2018 |
High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Topics: Adult; Anti-HIV Agents; China; Coinfection; DNA-Directed DNA Polymerase; Drug Resistance, Multiple, Viral; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Mutation; Prevalence; Tenofovir; Viral Load | 2018 |
Genotype Matters in Patients with Acute-on-chronic Liver Failure Due to Reactivation of Chronic Hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Virus Activation; Young Adult | 2018 |
A two-drug regimen for antiretroviral therapy.
Topics: Adult; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Tenofovir; Virus Activation; Young Adult | 2019 |
Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
Topics: Adult; Anti-HIV Agents; China; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Stavudine; Sustained Virologic Response; Tenofovir; Zidovudine | 2018 |
Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience.
Topics: Adult; Aging; Antiretroviral Therapy, Highly Active; Brain; Cognition; Cognitive Dysfunction; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Neuropsychological Tests; Quality of Life; Retrospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tenofovir | 2019 |
Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Calcium; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Hypocalcemia; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prevalence; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Symfi, Symfi Lo, and Cimduo for HIV.
Topics: Adenine; Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Interactions; HIV Infections; HIV-1; Humans; Lamivudine; Phosphorous Acids; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2019 |
Zidovudine, tenofovir or abacavir? Different adverse effect profiles.
Topics: Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2016 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Patient Compliance; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2019 |
Option B plus antiretroviral therapy adherence and associated factors among HIV positive pregnant women in Southern Ethiopia.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Directive Counseling; Drug Therapy, Combination; Ethiopia; Female; Health Services Accessibility; HIV Seropositivity; Hospitals, Public; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Medication Adherence; Pregnancy; Prenatal Care; Surveys and Questionnaires; Tenofovir; Time Factors; Travel; Young Adult | 2019 |
Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2019 |
Reply to Lanzafame et al.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Emtricitabine; HIV-1; Humans; Lamivudine; Tenofovir | 2019 |
DRIVE-AHEAD Trial's Results and the Need for a More Appropriate Comparator Drug.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Emtricitabine; HIV-1; Humans; Lamivudine; Tenofovir | 2019 |
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Stavudine; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study.
Topics: Alanine Transaminase; Antiviral Agents; Asian People; Black People; Deprescriptions; Disease Progression; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; North America; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Tenofovir; Viral Load | 2019 |
Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexp
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleotides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Medroxyprogesterone Acetate; Microbiota; Organophosphates; Pre-Exposure Prophylaxis; Tenofovir; Uganda | 2020 |
Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis.
Topics: Alkynes; Benzoxazines; Brain; Creatinine; Cyclopropanes; Humans; Lamivudine; Meningitis, Cryptococcal; Postmortem Changes; Tenofovir | 2019 |
In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.
Topics: Activating Transcription Factor 4; Adenine; Antiviral Agents; Apoptosis; Caspase 12; Cell Line; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Epithelial Cells; Female; Glomerular Filtration Rate; Heat-Shock Proteins; Hepatitis A Virus Cellular Receptor 1; Hepatitis B, Chronic; Humans; In Vitro Techniques; Interleukin-18; Kidney Tubules; Lamivudine; Lipocalin-2; Male; Middle Aged; Organophosphonates; Prospective Studies; Protective Agents; Renal Insufficiency, Chronic; Severity of Illness Index; Telbivudine; Tenofovir | 2019 |
Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
Topics: Adolescent; Cross-Sectional Studies; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Failure; Viral Load; Young Adult; Zimbabwe | 2019 |
Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2019 |
Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Sex Factors; Tenofovir; Young Adult; Zidovudine | 2020 |
Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon-alpha; Interleukin-10; Interleukin-12; Lamivudine; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Nucleosides; Organophosphonates; Proto-Oncogene Proteins c-akt; Tenofovir | 2020 |
Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Asian People; China; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2020 |
Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment.
Topics: Adult; Aged; Aging; Anti-HIV Agents; Area Under Curve; Dose-Response Relationship, Drug; Emtricitabine; Humans; Kidney Diseases; Kidney Function Tests; Lamivudine; Middle Aged; Models, Biological; Predictive Value of Tests; Tenofovir; Young Adult | 2019 |
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Genes, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load | 2019 |
HIV 101: fundamentals of antiretroviral therapy.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan.
Topics: Adult; Anti-Retroviral Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Female; Hemochromatosis; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Immunization Programs; Lamivudine; Male; Retrospective Studies; Seroepidemiologic Studies; Syphilis; Taiwan; Tenofovir; Young Adult | 2021 |
Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Microcephaly; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Puerto Rico; Tenofovir; Young Adult; Zidovudine | 2020 |
Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia.
Topics: Adolescent; Adult; Anti-HIV Agents; Eligibility Determination; Female; HIV Infections; Humans; Lamivudine; Malawi; Randomized Controlled Trials as Topic; Tenofovir; Zambia | 2020 |
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
Topics: Adult; Age Factors; CD4 Lymphocyte Count; Databases, Factual; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Lost to Follow-Up; Male; Medication Adherence; Middle Aged; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir; Treatment Failure; Viral Load; World Health Organization; Zidovudine | 2019 |
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Tenofovir; Treatment Failure; United Kingdom | 2020 |
Traditional Chinese Medicine Can Improve the Immune Reconstruction of HIV/AIDS Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; HIV Infections; Humans; Immune Reconstitution; Lamivudine; Medicine, Chinese Traditional; Middle Aged; Pilot Projects; Prospective Studies; T-Lymphocytes; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Kaposi's sarcoma in a HIV-positive patient: an exuberant and widespread case report in the Amazon.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Sarcoma, Kaposi; Skin Neoplasms; Tenofovir | 2020 |
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Mutation Rate; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Virus Replication; Zidovudine | 2020 |
Simple thin layer chromatography-ultraviolet spectrophotometric method for quality assessment of binary fixed-dose-combinations of lamivudine/tenofovir disoproxil fumarate and lamivudine/zidovudine in tablet formulations.
Topics: Anti-HIV Agents; Chromatography, Thin Layer; Drug Combinations; Drug Compounding; Lamivudine; Molecular Structure; Spectrophotometry, Ultraviolet; Tablets; Tenofovir; Zidovudine | 2020 |
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Sustained Virologic Response; Tenofovir | 2020 |
Movement disorder in a patient with Human Immunodeficiency Virus on an anti-retroviral therapy: A Case Report.
Topics: AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Brain Barrier; Brain Stem; Cerebellar Ataxia; Cerebellum; Cyclopropanes; Drug Substitution; Female; Gait Ataxia; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurodegenerative Diseases; Nystagmus, Pathologic; Panic Disorder; Pons; Postural Balance; Sensation Disorders; Tenofovir; Zidovudine | 2020 |
Monitoring the transition to new antiretroviral treatment regimens through an enhanced data system in Kenya.
Topics: Anti-HIV Agents; Data Systems; Database Management Systems; Drug Monitoring; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty.
Topics: Adult; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkitt Lymphoma; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cementoplasty; Cyclophosphamide; Cyclopropanes; Doxorubicin; Female; Fractures, Compression; HIV Infections; Humans; Kyphoplasty; Lamivudine; Lumbar Vertebrae; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Spinal Fractures; Tenofovir; Tomography, X-Ray Computed; Vincristine; Viral Load | 2020 |
Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Viremia; Young Adult | 2020 |
The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro.
Topics: Anti-HIV Agents; Drug Synergism; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir | 2020 |
Modeling cerebellar limb dysmetria and impaired spatial memory in rats using lamivudine: A preliminary study.
Topics: Alkynes; Animals; Benzoxazines; Cerebellar Ataxia; Cyclopropanes; Disease Models, Animal; Lamivudine; Male; Maze Learning; Rats; Rats, Wistar; Spatial Memory; Tenofovir | 2020 |
Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; Humans; Hypercalcemia; Hyperkalemia; Hyperphosphatemia; Hypocalcemia; Hypokalemia; Hypophosphatemia; Lamivudine; Male; Middle Aged; Prevalence; Proteinuria; Renal Insufficiency; Tenofovir; Uganda | 2020 |
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coronavirus Infections; COVID-19; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Hospitalization; Humans; Incidence; Intensive Care Units; Lamivudine; Male; Middle Aged; Pandemics; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Severity of Illness Index; Spain; Tenofovir | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir | 2020 |
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral sup
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Substitution; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Taiwan; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Rapid and efficient chiral method development for lamivudine and tenofovir disoproxil fumarate fixed dose combination using ultra-high performance supercritical fluid chromatography: A design of experiment approach.
Topics: Chromatography, Supercritical Fluid; Lamivudine; Reference Standards; Reproducibility of Results; Stereoisomerism; Tenofovir | 2020 |
Assessing the association between platelets and immune recovery in HIV/HBV co-infected patients: A long-term cohort in Asia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Platelets; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immune Reconstitution; Lamivudine; Longitudinal Studies; Male; Platelet Count; Retrospective Studies; Tenofovir | 2020 |
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Topics: Adult; Female; Government Programs; Health Facilities; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pregnancy; Pyridones; Qualitative Research; South Africa; Tenofovir; Uganda | 2020 |
Changes in bone microarchitecture with abacavir--lamivudine versus tenofovir disoproxil fumarate--emtricitabine in adults living with HIV.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Emtricitabine; Fractures, Bone; HIV Infections; Humans; Incidence; Lamivudine; Osteoporotic Fractures; Tenofovir | 2020 |
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles | 2020 |
Complex genetic encoding of the hepatitis B virus on-drug persistence.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2020 |
Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Private Sector; Retrospective Studies; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2020 |
In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Developmental Disabilities; Dideoxynucleosides; Emtricitabine; Exploratory Behavior; Female; Fetal Growth Retardation; Growth Disorders; Hand Strength; HIV Protease Inhibitors; Homing Behavior; Lamivudine; Male; Mice; Mice, Inbred C57BL; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Reflex, Abnormal; Reflex, Righting; Sensation Disorders; Taxis Response; Tenofovir | 2020 |
Efficacy of Nucleotide/Nucleoside Analogues and Hepatitis B Immunoglobulin Therapy in Blocking Mother-to-Child Transmission of Hepatitis B in an Eastern Chinese Group.
Topics: Antiviral Agents; Case-Control Studies; China; DNA, Viral; Drug Administration Schedule; Female; Gestational Age; Hepatitis B; Hepatitis B Antigens; Hepatitis B virus; Humans; Immunoglobulins; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Telbivudine; Tenofovir; Treatment Outcome | 2020 |
A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; North America; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2021 |
A simple alternative and improved HPLC method for the estimation of doravirine, lamivudine, and tenofovir disoproxil fumarate in solid oral dosage form.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Lamivudine; Limit of Detection; Linear Models; Pyridones; Reproducibility of Results; Tablets; Tenofovir; Triazoles | 2021 |
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; South Africa; Tenofovir; Viral Load | 2021 |
A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets.
Topics: Chromatography, High Pressure Liquid; Lamivudine; Pyridones; Tablets; Tenofovir; Triazoles | 2021 |
Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settings.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2021 |
Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Myocardial Infarction; Tenofovir; United States | 2021 |
Development and validation of ultra performance liquid chromatography-tandem mass spectrometry method for the simultaneous estimation of dolutegravir, lamivudine and tenofovir in bulk and tablet dosage form.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Heterocyclic Compounds, 3-Ring; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets; Tandem Mass Spectrometry; Tenofovir | 2021 |
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya.
Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kenya; Lamivudine; Oxazines; Peptide Hydrolases; Piperazines; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Tenofovir | 2022 |
Brief Report: Patients' Experiences and Opinions After Desimplification of Their Single-Tablet Regimens for the Treatment of HIV Infection: A Survey in a Multicentre Cohort.
Topics: Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Quality of Life; Surveys and Questionnaires; Tablets; Tenofovir | 2022 |
Response to 'The use of tenofovir in patients with COVID-19'.
Topics: Antiviral Agents; COVID-19 Drug Treatment; HIV Infections; Humans; Lamivudine; Tenofovir | 2022 |
Senescence and oxidative stress toxicities induced by lamivudine and tenofovir in Drosophila melanogaster.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antioxidants; Biomarkers; Catalase; DNA, Viral; Drosophila melanogaster; Glutathione; Glutathione Transferase; Humans; Lamivudine; Malondialdehyde; Molecular Docking Simulation; Oxidative Stress; RNA-Directed DNA Polymerase; Sulfhydryl Compounds; Superoxide Dismutase; Tenofovir | 2022 |
Weight gain during the dolutegravir transition in the African Cohort Study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Topics: Adult; Amides; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Cohort Studies; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2022 |
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.
Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load | 2022 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |
Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Brazil; Cohort Studies; HIV Infections; Humans; Lamivudine; Prospective Studies; Tenofovir | 2023 |
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Topics: Anti-HIV Agents; COVID-19; COVID-19 Testing; Emtricitabine; HIV Infections; Humans; Lamivudine; Propensity Score; Prospective Studies; SARS-CoV-2; Tenofovir | 2022 |
Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lesotho; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Prospective Studies; Self Report; Tenofovir | 2023 |
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV.
Topics: Anti-HIV Agents; Cohort Studies; COVID-19; COVID-19 Testing; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; SARS-CoV-2; Tenofovir | 2022 |
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2022 |
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Malawi; Oxazines; Piperazines; Prospective Studies; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2022 |
Do anti-HIV drugs pose a threat to photosynthetic microorganisms?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Lamivudine; Photosynthesis; Tenofovir; Water | 2022 |
Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Prospective Studies; Pyridones; Tenofovir; Uganda; Viral Load | 2022 |
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Emtricitabine; HIV Infections; Humans; Interleukin-6; Lamivudine; Middle Aged; Nevirapine; Tenofovir; Weight Loss; Zidovudine | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Observ
Topics: Adult; Creatinine; Cystatin C; Female; Glomerular Filtration Rate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir | 2022 |
A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues.
Topics: Anti-HIV Agents; Autopsy; Benzoxazines; Chromatography, Liquid; Female; Fluconazole; Genitalia, Female; HIV Infections; Humans; Lamivudine; Tandem Mass Spectrometry; Tenofovir | 2022 |
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer.
Topics: Amides; Anti-HIV Agents; Colorectal Neoplasms; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Integrase Inhibitors; Lamivudine; Piperazines; Pyridones; Raltegravir Potassium; Tenofovir | 2022 |
Economic evaluation of doravirine/tenofovir disoproxil fumarate/lamivudine for HIV-1-infected adults in Russia: a cost-minimization and budget impact analysis.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Drug Combinations; Drugs, Essential; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; RNA, Viral; Tenofovir; Viral Load | 2022 |
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Pyridones; RNA, Viral; Tablets; Tenofovir | 2023 |
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Creatinine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Prospective Studies; Pyridones; RNA; Tenofovir; Triglycerides | 2022 |
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation].
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Rilpivirine; Tenofovir | 2021 |
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; COVID-19; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Middle Aged; SARS-CoV-2; Tenofovir | 2022 |
Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Hypertriglyceridemia; Lamivudine; Tenofovir | 2022 |
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Cameroon; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load | 2022 |
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Viral Load; Viremia | 2023 |
Epidemiology of Tuberculosis Among People Living With HIV in the African Cohort Study From 2013 to 2021.
Topics: CD4 Lymphocyte Count; Cohort Studies; HIV Infections; Humans; Incidence; Lamivudine; Risk Factors; Tenofovir; Thinness; Tuberculosis | 2023 |
A Perspective into "TEL"-Tenofovir, Emtricitabine and Lamivudine Antileprotic Activities by Drug Repurposing and Exploring the Possibility of Combination Chemotherapy with Drug Rescued Molecules for a Leprosy Free Mankind.
Topics: Anti-HIV Agents; Drug Repositioning; Drug Therapy, Combination; Emtricitabine; Humans; Lamivudine; Leprosy; Molecular Docking Simulation; Mycobacterium leprae; Tenofovir | 2023 |
Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Incidence; Lamivudine; Male; Retrospective Studies; Risk Factors; Tenofovir; Triglycerides | 2023 |
Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mutation; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Treatment Failure; Vietnam | 2023 |
Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
Topics: Adult; Anti-HIV Agents; Bone Density; Cancellous Bone; East Asian People; HIV Infections; Humans; Lamivudine; Male; Muscles; Osteoporosis; Retrospective Studies; Sarcopenia; Stavudine; Tenofovir; Young Adult | 2023 |
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil.
Topics: Anti-Retroviral Agents; Brazil; HIV Infections; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2023 |
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Topics: China; Drug Combinations; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Tenofovir | 2023 |
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Lamivudine; Male; Pediatrics; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2023 |
Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
Topics: Aldo-Keto Reductase Family 1 member B10; Aldo-Keto Reductases; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Tenofovir | 2023 |
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Topics: Adsorption; Ammonium Hydroxide; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Chromatography, Liquid; Emtricitabine; HIV Infections; Humans; Lamivudine; Methanol; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Water | 2023 |
Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
Topics: Child; Developing Countries; Drugs, Generic; HIV Infections; Humans; Lamivudine; Tenofovir; United States | 2023 |
Exposure to doravirine, lamivudine, tenofovir, and raltegravir in a patient with HIV after a Roux-en-Y gastric bypass.
Topics: Gastric Bypass; HIV Infections; Humans; Lamivudine; Raltegravir Potassium; Tenofovir | 2023 |
Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens.
Topics: Cameroon; HIV Seropositivity; HIV-1; Humans; Lamivudine; Tenofovir | 2023 |
A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.
Topics: Animals; Anti-HIV Agents; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Lamivudine; Leukocytes, Mononuclear; Oxazines; Pharmaceutical Preparations; Pyridones; Tenofovir | 2023 |
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Unrestricted access to tenofovir, lamivudine, and dolutegravir as pre-exposure or post-exposure prophylaxis in community settings.
Topics: Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Post-Exposure Prophylaxis; Tenofovir | 2023 |
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.
Topics: Africa, Western; Cost-Benefit Analysis; Female; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2023 |
First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers.
Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Lamivudine; Mothers; Oxazines; Pregnancy; Tenofovir | 2023 |
Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.
Topics: Adult; Humans; Lamivudine; Prevalence; Prospective Studies; Tenofovir; Zimbabwe | 2023 |
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Retroviral Agents; Child; COVID-19; Hepatitis C; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Tenofovir | 2023 |
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Tenofovir; Treatment Adherence and Compliance | 2023 |
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir | 2023 |
Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Hormonal Contraception; Humans; Lamivudine; Levonorgestrel; Malawi; Medroxyprogesterone Acetate; Microbiota; Tenofovir; Vagina | 2023 |
Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
Topics: Adult; Coinfection; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Retrospective Studies; Tenofovir | 2023 |
Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Topics: Child; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Risk Factors; Seroepidemiologic Studies; Tenofovir | 2023 |